US20070225696A1 - Surgical apparatus for laser ablation of soft tissue - Google Patents
Surgical apparatus for laser ablation of soft tissue Download PDFInfo
- Publication number
- US20070225696A1 US20070225696A1 US11/614,265 US61426506A US2007225696A1 US 20070225696 A1 US20070225696 A1 US 20070225696A1 US 61426506 A US61426506 A US 61426506A US 2007225696 A1 US2007225696 A1 US 2007225696A1
- Authority
- US
- United States
- Prior art keywords
- laser
- tissue
- diode
- surgical apparatus
- power
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
- A61B18/20—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
- A61B18/20—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
- A61B18/22—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser the beam being directed along or through a flexible conduit, e.g. an optical fibre; Couplings or hand-pieces therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B17/00—Surgical instruments, devices or methods, e.g. tourniquets
- A61B17/00234—Surgical instruments, devices or methods, e.g. tourniquets for minimally invasive surgery
- A61B2017/00238—Type of minimally invasive operation
- A61B2017/00274—Prostate operation, e.g. prostatectomy, turp, bhp treatment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00315—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for treatment of particular body parts
- A61B2018/00547—Prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00571—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body for achieving a particular surgical effect
- A61B2018/00625—Vaporization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B2018/00982—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body combined with or comprising means for visual or photographic inspections inside the body, e.g. endoscopes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
- A61B18/20—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
- A61B2018/2015—Miscellaneous features
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B18/00—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body
- A61B18/18—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves
- A61B18/20—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser
- A61B18/22—Surgical instruments, devices or methods for transferring non-mechanical forms of energy to or from the body by applying electromagnetic radiation, e.g. microwaves using laser the beam being directed along or through a flexible conduit, e.g. an optical fibre; Couplings or hand-pieces therefor
- A61B2018/2255—Optical elements at the distal end of probe tips
- A61B2018/2272—Optical elements at the distal end of probe tips with reflective or refractive surfaces for deflecting the beam
Definitions
- the present invention relates generally to laser treatment of soft tissue, and more particularly to photoselective vaporization of the prostate PVP, and to photoselective vaporization of other tissue.
- Benign Prostatic Hyperplasia is a condition wherein continued growth of the prostate restricts the passage of urine through the lower portion of the bladder and the urethra. BPH is often treated by surgically removing excess prostate tissue from the transitional zone of the prostate that is pressing on the urethra, which usually relieves the bladder outlet obstruction and incomplete emptying of the bladder caused by the BPH.
- TURP transurethral resection of the prostate
- the surgeon utilizes a standard electrical cutting loop to shave off small pieces of the targeted tissue from the interior of the prostate.
- pieces of excised prostate tissue are flushed out of the bladder using an irrigant.
- thermal procedures Because these procedures leave the thermally-treated tissue in place, post-procedure edema, dysuria, and retention rates are relatively high. Further, use of thermal procedures requires the patient to be catheterized for several days following the procedure, and may cause extensive and unpredictable scarring of the intra prostatic urethra.
- Another class of procedures involves vaporizing or ablating the targeted tissue using laser light. These procedures generally avoid the high infection rates and scarring problems of thermally-based procedures.
- laser ablation of prostate tissue has to date, required the use of an expensive laser capable of generating high-power laser light. The high cost of purchasing or leasing such a laser results in a concomitant increase in the cost of the procedure. Finally, the ablation process typically occurs slowly, resulting in a lengthy procedure time.
- the Ho:YAG laser and its fiberoptic delivery system is an example of a laser that is commonly used for ablating prostate tissue.
- the Ho:YAG laser generates pulses of 2100 nm light that are strongly absorbed by water in the prostate tissue and in the saline irrigant positioned between the distal end if the fiberoptic and the tissue.
- the absorption coefficient of water is so high at 2100 nm that 50% of the light is absorbed within 0.2 mm of water. Consequently even a thin layer of irrigant positioned between the distal end on the fiberoptic and the tissue will absorb a large fraction of the laser light.
- Nd:YAG lasers operating at 1064 nm have also been used for ablating prostate tissue. Although 1064 nm light is hemostatic at high power levels its low absorption in blood and prostate tissue leads to inefficient ablation and a large residual layer of thermally denatured tissue several millimeters thick. After surgery, the coagulated, thermally denatured tissue swells and leads to transient urinary retention, which can cause long catheterization times, painful urination, and high infection rates.
- Frequency doubled Nd:YAG lasers operating at 532 nm in a Quasi continuous mode at power levels up to 60 watts have been used to efficiently and hemostatically ablate prostate tissue. These lasers are pumped by CW krypton arc lamps and produce a constant train of Q-switched pulses at 25 kHz. The high Q-Switch frequency makes the tissue effects indistinguishable from CW lasers of the same average power. The 532 nm light from these lasers is selectively absorbed by blood leading to good hemostasis. When ablative power densities are used, a superficial layer of denatured prostate tissue less than 1 mm is left behind.
- This thin layer of denatured tissue is thin enough that the immediate post surgical swelling associated with other treatment modalities is greatly reduced. This reduced swelling leads to short catheterization times and less dysuria.
- 532 nm lasers induce a superficial char layer (an absorptive, denatured layer) that strongly absorbs the laser light and greatly improves the ablation efficiency.
- the problem with the existing 532 nm lasers used to date is that they are large, expensive, inefficient, and have a highly multi-mode output beam that makes them inefficient for ablating prostate tissue.
- residual coagulation of tissue due to the procedure remains significant using the techniques known in the prior art, as discussed below.
- High power densities are required for rapid and efficient vaporization of prostate tissue.
- the difficulty of achieving higher average output power densities is that when high input powers are supplied to the laser element from an excitation source such as an arclamp a large amount of heat is generated in the lasing element. This heat induces various deleterious effects in the lasing element.
- the temperature difference between the coolant and the hot lasing element generates a thermally induced graded index lens that decreases the beam quality of the laser and causes the laser to operate with more transverse optical modes than it would otherwise.
- the M 2 parameter is a well established convention for defining the beam quality of a laser and is discussed in pages 480-482 of Orazio Svelto and David C. Hanna, Principles of Lasers , Plenum Press, New York, 1998, which is incorporated herein by reference.
- the beam quality measures the degree to which the intensity distribution is Gaussian.
- the quantity M 2 is sometimes called inverse beam quality rather than beam quality but in this application it will be referred to as beam quality.
- ⁇ refers to the number 3.14 . . . , ⁇ is used to represent the spot size
- the subscripts x and f represent the spatial and frequency domains along the x-axis, respectively
- the subscripts G and NG signify Gaussian and non-Gaussian, respectively.
- the x-axis is transverse to the direction of propagation of the beam. The beam quality in any direction transverse to the beam may be essentially the same. Therefore the subscript x is dropped from the M 2 elsewhere in the specification.
- the beam widths or us are determined based on the standard deviation of the position, where the squared deviation of each position is weighted by the intensity at that point.
- the beam width in the frequency domain ⁇ f is the beam width of the beam after being Fourier transformed.
- the formula usually used for calculating the angular divergence, ⁇ , of a beam of light of wavelength ⁇ is strictly valid only for a beam having a Gaussian intensity distribution.
- a TEM00 laser beam has a high beam quality with an M 2 of 1, whereas by comparison, high power surgical lasers operate with M 2 values greater than 100.
- high power lasers typically have an M 2 >144.
- M 2 the larger number of modes makes M 2 larger and makes it difficult to focus the light into small, low numerical aperture fibers and reduces the ability to project high power density light onto tissue.
- the vaporization efficiency of CW arclamp pumped 532 nm lasers on prostate tissue is significantly reduced.
- Photoselective vaporization of tissue is based upon applying a high intensity radiation to prostate tissue using a radiation that is highly absorptive in the tissue, while being absorbed only to a negligible degree by water or other irrigant during the operation, at power densities such that the majority of the energy is converted to vaporization of the tissue without significant residual coagulation of adjacent tissue.
- the procedure may be conducted under local anesthesia, and patients are usually able to go home a couple of hours after the procedure. The procedure results in fewer side effects than prior art techniques, including lower incidence of dysuria and hemouria. Patients may be treated without requiring post-operative catherization of the urethra.
- a method for treating BPH comprises the steps of providing a solid-state laser having a laser element positioned to receive pump radiation from an excitation source; in some cases modulating the source to cause the laser to emit pulsed laser light; and delivering the laser light to targeted tissue.
- Various solid-state lasers may be used for this purpose, including (without limitation), a Q-switched laser using a frequency doubling crystal such as potassium-titanyl-phosphate (KTP), pumped using a diode array, an arc lamp or a flash lamp.
- KTP potassium-titanyl-phosphate
- a “macro-pulse” duration of the laser light is preferably in the range of 0.1 to 500 milliseconds, induced by for example modulating the pump energy with the desired macro-pulse length.
- the wavelength of the laser light is preferably between 200 and 1000 nm.
- the laser light is preferably delivered to the targeted prostate tissue through an optical fiber terminating at or near a distal end in a side-firing probe. However the side-firing probe is not essential.
- Operation of the solid-state laser in a “macro-pulsed” mode is more efficient in inducing rapid tissue ablation than a CW laser of the same average power. This is in part because the macro-pulsing is more efficient in inducing “char” formation, a mild carbonization in which the tissue typically darkens slightly but does not necessarily turn completely black. Although char formation is not essential to efficient rapid ablation it is helpful because the darkened tissue is better at absorbing light.
- the macro-pulsed laser is also more efficient and has higher beam quality, with M 2 values typically less than 144, than a continuous wave laser with same average output power.
- a method for treating soft tissue comprises the steps of providing a solid-state laser having a laser element positioned to receive pump radiation from a pump radiation source; modulating the pump radiation source to cause the laser element to emit laser light having a pulse duration of between 0.1 milliseconds and 500 milliseconds and an output power exceeding 20 watts; and delivering the laser light to targeted tissue.
- a method for treating BPH comprises the steps of providing a solid-state laser having a laser element positioned to receive pump radiation from a pump radiation source; Q-switching the laser to generate a quasi-continuous wave (CW) beam having an output power exceeding 60 watts; and, delivering the beam to targeted prostate tissue.
- CW quasi-continuous wave
- a method for treating BPH comprises the steps of providing a solid-state laser having a laser element positioned to receive pump radiation from a pump radiation source such as a laser diode; Q-switching the laser to generate a quasi-continuous wave (CW) beam having an output power exceeding 20 watts with an M 2 less than 144; and delivering the beam to prostate tissue.
- a pump radiation source such as a laser diode
- the invention provides a method for photoselective vaporization of prostate tissue.
- the method includes delivering laser radiation to the treatment area on the tissue, via an optical fiber for example, wherein the laser radiation has a wavelength and irradiance in the treatment area on the surface of the tissue sufficient because vaporization of a substantially greater volume of tissue than a volume of residual coagulated tissue caused by the laser radiation.
- the laser radiation is generated using a neodymium doped solid-state laser, including optics producing a second or higher harmonic output with greater than 60 watts average output power, and for example 80 watts average output power, or more.
- the laser radiation is coupled into an optical fiber adapted to direct laser radiation from the fiber to the treatment area on the surface of the tissue.
- the fiber optic is inserted via transurethral cystoscope, including lumens for delivering irrigants to the treatment area, and for direct visualization during the treatment.
- the delivered laser radiation has a wavelength in a range of about 200 nm to about 650 nm, and has an average irradiance in the treatment area greater than about 10 kilowatts/cm 2 , in a spot size of at least 0.05 mm 2 . More preferably, the irradiance is greater than about 20 kilowatts/cm 2 , and even more preferably greater than about 30 kilowatts/cm 2 .
- the spot size in preferred systems is for example less than about 0.8 mm 2 .
- the second harmonic output of the neodymium dope solid-state laser is applied using a side firing tip on the optical fiber.
- the side firing tip which causes a diverging beam to be directed out of the optical fiber, is placed close to the tissue, within about 1 mm from the side of the side firing tip to contacting the side of the tip. Close placement increases the irradiance delivered to the treatment area so that higher irradiance is available with solid-state lasers generating a 60 to 80 watts average output power.
- a procedure according to the present invention includes applying intraurethral topical anesthesia such as lidocaine, either a periprostatic block or a perirectal block, oral and/or intravenous drugs such as Fentanyl or Demerol, chilled irrigant, and irrigant containing anesthesia.
- intraurethral topical anesthesia such as lidocaine, either a periprostatic block or a perirectal block
- oral and/or intravenous drugs such as Fentanyl or Demerol, chilled irrigant, and irrigant containing anesthesia.
- embodiments of the invention include the delivery of the laser energy using a Q-switched, solid-state laser which produces micro-pulses in combination with applying pump power to the laser medium in a sequence a pulses so that output radiation is produced in macro-pulses having a peak power of greater than 200 watts, and more preferably about 240 watts or greater.
- the peak irradiance in the treatment area during the pulses is thereby substantially increased, and preferably greater than 50 kilowatts/cm 2 , and as much as 90 kilowatts/cm 2 in some embodiments of the invention.
- FIG. 1 depicts a laser system for implementing the tissue ablation methods of the invention
- FIG. 2 depicts a side-firing probe for use with the system of FIG. 1 ;
- FIG. 3 depicts an exemplary output waveform of the FIG. 1 laser when the laser is operated in a macro-pulsed mode
- FIG. 4 depicts an exemplary output waveform of the FIG. 1 laser when the laser is operated in a quasi-CW mode.
- FIG. 5 is a block diagram of a laser system adaptable for use according to the present invention.
- FIG. 6 is a block diagram of an alternative laser system adaptable for use according to the present invention.
- FIG. 7 is a diagram of a transurethral cystoscope, adaptable for use according to the present invention.
- FIG. 8 illustrates absorption depth in prostate tissue for 532 nm light.
- FIG. 9 illustrates absorption depth in prostate tissue for 1064 nm light.
- FIG. 10 is a diagram of a beam path from an end view of a side firing tip, according to one embodiment of the present invention.
- FIG. 11 is a diagram of a beam path from a side view of the side firing tip of FIG. 10 , according to one embodiment of the present invention.
- FIG. 12 is a heuristic diagram illustrating operation of the present invention.
- FIG. 1 is a block diagram depicting an exemplary laser system 100 which may be employed for implementing the present invention.
- Laser system 100 includes a solid-state laser 102 , which is used to generate laser light for delivery through optical fiber 106 to target tissue 104 .
- laser 102 is capable of being operated in a “macro-pulsed” mode, wherein the laser light is emitted as macro-pulses having relatively long pulse durations.
- Laser 102 more specifically comprises a laser element assembly 110 , pump source 112 , and frequency doubling crystal 122 .
- laser element 110 outputs 1064 nm light which is focused into frequency doubling crystal 122 to create 532 nm light.
- laser element assembly 110 may be neodymium doped YAG (Nd:YAG) crystal, which emits light having a wavelength of 1064 nm (infrared light) when excited by pump source 112 .
- Laser element 110 may alternatively be fabricated from any suitable material wherein transition and lanthanide metal ions are disposed within a crystalline host (such as YAG, Lithium Yttrium Fluoride, Sapphire, Alexandrite, Spinel, Yttrium Orthoaluminate, Potassium Gadolinium Tungstate, Yttrium Orthovandate, or Lanthanum Scandium Borate).
- a crystalline host such as YAG, Lithium Yttrium Fluoride, Sapphire, Alexandrite, Spinel, Yttrium Orthoaluminate, Potassium Gadolinium Tungstate, Yttrium Orthovandate, or Lanthanum Scandium Borate.
- Laser element 110 is positioned proximal to pump source 112 and may be arranged in parallel relation therewith, although other geometries and configurations may be employed.
- Pump source 112 may be any device or apparatus operable to excite laser element assembly 110 .
- Non-limiting examples of devices which may be used as pump source 112 include: arc lamps, flashlamps, and laser diodes.
- a Q-switch 114 disposed within laser 102 may be operated in a repetitive mode to cause a train of micro-pulses to be generated by laser 102 .
- the micro-pulses are less than 1 microsecond in duration separated by about 40 microseconds, creating a quasi-continuous wave train.
- Q-switch 114 is preferably of the acousto-optic type, but may alternatively comprise a mechanical device such as a rotating prism or aperture, an electro-optical device, or a saturable absorber.
- Control system 116 for controlling and operating laser 102 .
- Control system 116 will typically include a control processor which receives input from user controls (including but not limited to a beam on/off control, a beam power control, and a pulse duration control) and processes the input to accordingly generate output signals for adjusting characteristics of the output beam to match the user inputted values or conditions.
- control system 116 applies an output signal to a power supply (not shown) driving pump source 112 which modulates the energy supplied thereto, in turn controlling the pulse duration of the output beam.
- FIG. 1 shows an internal frequency doubled laser, it is only by way of example.
- the infrared light can be internally or externally frequency doubled using non-linear crystals such as KTP, Lithium Triborate (LBO), or Beta Barium Borate (BBO) to produce second harmonic 532 nm green light, and higher harmonics.
- non-linear crystals such as KTP, Lithium Triborate (LBO), or Beta Barium Borate (BBO) to produce second harmonic 532 nm green light, and higher harmonics.
- the frequency doubled, 532 nm wavelength and the shorter wavelength higher harmonic beams are better absorbed by the tissue, and promote more efficient tissue ablation.
- the resonant cavity control system is that described in U.S. Pat. No. 5,151,909, which is incorporated by reference as if fully set forth herein.
- Laser 102 further includes an output port couplable to optical fiber 106 .
- Output port 118 directs the light generated by laser 102 into optical fiber 106 for delivery to tissue 104 .
- Mirrors 124 , 126 , 128 , and 130 direct light from the lasing element 110 to the frequency doubling crystal 122 , in addition to forming the resonant cavity of the laser.
- Mirrors 124 , 126 , 128 , and 130 are configured for focusing the light to form an image just in front of the frequency doubling crystal 122 on the side closer to mirror 130 , and to compensate for thermal lensing in the lasing element.
- mirrors 124 , 126 , 128 , and 130 are illustrated as flat and parallel to the walls of the laser, typically the focusing is achieved by curving and/or angling the mirrors. Alternatively transmissive optical elements could be used to focus the light and compensate for the thermal imaging.
- Mirrors 124 , 128 and 130 reflect both the wavelength of light produced by the lasing element (e.g. 1064 nm) and the wavelength of the frequency doubled light (e.g. 532 nm).
- Mirror 126 only reflects the light originating from the lasing element 110 (e.g. 1064 nm) but is transparent to the frequency doubled light (e.g. 532 nm), forming an output window.
- Higher harmonic outputs may also be generated from the 1064 nm line, or other line amplified in the laser, including third and fourth harmonics, for shorter wavelengths.
- Other laser systems may be used, including but not limited to Sapphire lasers, diode lasers, and dye lasers, which are adapted to provide the output power and wavelengths described herein, including wavelengths in the ranges from 200 nm to 1000 nm and from 1100 nm to 1800 nm, for example.
- optical fiber 106 preferably terminates in a tip 140 having optical elements for shaping and/or orienting the beam emitted by optical fiber 106 so as to optimize the tissue ablation process.
- FIG. 2 depicts a side-firing probe tip 200 , which may be used as tip 140 ( FIG. 1 ).
- the tip 140 is treated to deflect light sideways.
- Some examples of methods for deflecting the light sideways are to include a light scattering material in the tip 140 and/or to place a reflective element in the tip 140 .
- the reflective element could be angled at 45°, for example; to deflect the light at 90° with respect to the axis of the fiber 106 .
- Side-firing probe tip 200 includes an optically transparent sleeve 202 having a transparent window 204 (which may be constructed as a cutout in the wall of sleeve 202 through which the beam is emitted in a direction transverse to the optical axis of fiber 106 .)
- An acceptable range of angles in which to deflect the light beam is between about 40 to 120 degrees with respect to the axis of the fiber.
- the preferred embodiments use an angle of either 70 or 100.
- the angle of 80° is preferred from the standpoint of the ease in manufacturing the tip 200 and the angle of 90° is preferred from the standpoint of the ease in aiming the side firing light.
- optical fiber 106 is held within an endoscope such as a cystoscope or similar instrument that allows the clinician to precisely position the distal end of the optical fiber adjacent to the targeted tissue.
- the endoscope also has channels for supplying and removing an irrigant solution to and from the tissue.
- light and image guides are also included for illuminating and imaging the tissue so that the clinician may direct the laser light and assess the progress and efficacy of the ablation procedure.
- FIG. 3 illustrates an exemplary output waveform applied to tissue 104 when laser 102 is operated in the macro-pulsed mode.
- Each macro-pulse 302 is defined by a train of Q-switched micro-pulses 304 . While a relatively small number of micro-pulses 302 are depicted for purposes of clarity, an actual macro-pulse may comprise hundreds or thousands of component micro-pulses 304 . In the preferred embodiment there are between 2 and 12,200 micro-pulses per macro-pulse.
- An arc lamp for example, when used as the pump source 112 , is kept at a low power level between pulses that are preferably just enough to maintain the arc. These low pump powers are below the lasing threshold of the laser; as a consequence, there is no laser output between macro-pulses.
- the pulse duration or width D ( FIG. 3 ) of the output beam is governed by the modulation of pump source 112 , and more specifically by the period during which the pump source 112 is maintained in an “on” or high-power condition.
- laser 102 will be capable of delivering pulses 302 having pulse durations D in the range of 1 to 20 milliseconds (2 to 490 micro-pulses) or 1 to 50 milliseconds (2 to 1,220 micro-pulses) and average output powers preferably exceeding 60 watts and preferably up to 100 or 200 watts.
- the ratio of D to the period of the macro-pulses defines the duty cycle, which is typically between 10 and 50%.
- a laser system 100 of the foregoing description is employed to treat BPH by ablating targeted prostate tissue 104 .
- the clinician may utilize an endoscope or similar instrument to guide the distal end and tip 140 of optical fiber 106 into alignment with the targeted prostate tissue 104 .
- Laser system 100 is then operated in the macro-pulsed mode so that laser 102 generates laser light having the pulsed waveform depicted in FIG. 3 and delivers it through optical fiber 106 to tissue 104 .
- irradiation of prostate tissue 104 may initially cause tissue heating resulting in the formation of a char layer.
- This char layer is highly optically absorptive in the wavelengths emitted by laser 102 , which thereby facilitates efficient absorption of the laser light and resultant ablation of tissue 104 .
- the formation of the char layer is not essential for efficient ablation.
- Prior art techniques for treatment of BPH by laser ablation such as the technique described by Kuntzman et al. in “High-Power (60-Watt) Potassium-Titanyl-Phosphate Laser Vaporization Prostatectomy in Living Canines and in Human and Canine Cadavers,” Urology , Vol. 49, No.
- the macropulsing can also increase efficiency because the threshold voltage required for lasing while macropulsing (the operating threshold) is lower than the initial threshold voltage for lasing (cold threshold).
- Macropulsing is also more efficient for producing green light because the conversion of infrared light to frequency doubled light increases as the square of the infrared light intensity.
- the higher peak powers of the macro-pulsed infrared light leads to higher second harmonic conversion efficiency.
- A is an experimentally determined positive constant.
- This equation relates the peak input power to the peak output power.
- decreasing the duty cycle from 100% to 50% (i.e. reducing k from 1 to 0.5) while simultaneously doubling the peak input power Pi results in no change to the average input power ⁇ Pi> and a doubling of the average output power ⁇ Po>.
- Pulse modulating or macropulsing using Q-switching for example, enables reaching higher average output powers with less thermal lensing due to the lower input power.
- the frequency doubling crystal has nonlinearly increasing output power as a function of the input power.
- the second derivative of the output power with respect to the input power may be positive, in which case the rate of increase of the output power increases with increasing input power.
- the functional dependence of the instantaneous or peak output power, Po, on the instantaneous or peak input power, Pi is such that d 2 ( Po )/ d ( Pi ) 2 >0.
- Pump source modulation of the laser can produce high peak power macro-pulses and affect the efficiency of the average power output.
- Macro-pulse in excess of a steady state power can substantially improve the initiation of the vaporization of prostate tissue.
- the higher peak power of the macro-pulse rapidly initiates charring which in turn serves as an additional chromophore for the incident energy and enhances the vaporization rate.
- a 30% macro-pulse duty cycle is sufficient to increase the average power output of an arc lamp pumped laser to greater than 80 watts. Additionally the pump modulation generates macro-pulse with pulse powers greater than 240 watts.
- prostate tissue 104 may be efficiently and rapidly ablated when laser 102 is operated at an output power of 80 to 100 watts, a pulse duration of 1-50 milliseconds, and a wavelength of 532 nm.
- laser system 100 may be utilized to ablate other types of tissue 104 .
- Treatment of tissue 104 is performed in a manner substantially identical to the technique for treating BPH disclosed above.
- the clinician may utilize an endoscope or similar instrument to guide the distal end and tip 140 of optical fiber 106 into alignment with the prostate tissue 104 .
- Laser system 100 is then operated in the macro-pulsed mode so that laser light having the pulsed waveform depicted in FIG. 3 is generated by laser 102 and delivered through optical fiber 106 to tissue 104 .
- laser system 100 is adjusted to emit a beam having a pulse duration between 0.1 and 500 milliseconds, and an output power of at least 20 watts.
- the output beam of laser 102 is turned off.
- treatment of BPH is effected by operating laser 102 in a quasi-CW mode at an output power greater than 60 watts.
- the increased denaturization of the tissue is dramatic with increases in power, suggesting a threshold effect.
- laser 102 generates a continuous train of Q-switched micro-pulses 400 when operated in quasi-CW mode.
- the laser light is then delivered via optical fiber 106 to targeted tissue 104 .
- Operation in a quasi-CW mode at powers above 60 watts facilitates formation of char and consequent rapid ablation rates, whereas operation in a quasi-CW mode at powers below 60 watts forms char more slowly and causes more thermal damage to underling tissue.
- a fourth embodiment of this invention is to produce a high power, high beam quality laser that can project high power density laser light onto tissue. To do this the number of transverse optical modes supported by the resonator needs to be kept as low as possible.
- Small M 2 and high average powers can be achieved by reducing the degree of thermal lensing in the laser element.
- Using laser diodes as the excitation source is one effective way of greatly reducing both the size of the lasing element and the thermal gradient responsible for creating the thermal lens. The reason for this is that while 2-10% of the light produced from a flashlamp or arc lamp is converted into useful laser light 30-60% of the light emitted from laser diodes can be converted to laser light. Since the energy that is not converted to laser light is converted into heat, laser diodes deposit significantly less heat in the lasing element and as a consequence create a less powerful thermal lens. In this manner laser diodes can be used to pump crystalline laser elements or fiber lasers to produce high beam quality lasers.
- Slab and waveguide lasers that can be pumped by laser diodes, arc lamps, or flashlamps are another method of creating low M 2 lasers. This is because the thermal gradient produced in slab lasers is linear across the thin dimension of the slab and not radially dependent in contrast to a typical cylindrical lasing element. The linear thermal gradient does not produce a thermal lens resulting in low M 2 values.
- some embodiments of this invention are capable producing laser light that upon exiting a flat end of a fiber having a diameter of 600 ⁇ m has a divergence of 15.3° or lower; 15° or lower; 10° or lower; or 5° or lower, and the power density can be 13,400 watts per cm 2 , or greater.
- FIG. 5 shows a block diagram of a preferred laser system according to the present invention.
- a laser resonator is defined by end mirror 10 , turning mirrors 12 and 14 , and end mirror 16 . All of these mirrors are high reflecting (greater than 99.8%) at the 1064 nm line.
- An optical path 24 is defined by these mirrors.
- a gain medium 18 comprising a Nd:YAG rod is mounted along the optical path within a lamp housing 29 .
- An arc lamp 28 is also mounted within the housing and supplies pump power to the gain medium in response to current generated in power supply 30 .
- Also in the optical path 24 is a Q-switch 20 between the lamp housing 29 and the turning mirror 12 .
- a non-linear crystal 22 is mounted between the turning mirror 14 and the back mirror 16 .
- This non-linear crystal is preferably a KTP crystal aligned for frequency doubling to generate a 532 nm beam.
- Mirrors 16 and 14 are highly reflective at 532 nm, while mirror 12 is transmissive and operates as an output coupler for the 532 nm beam.
- the laser resonator is designed for resonating at a first frequency, i.e., 1064 nm along the Z-shaped optical path 24 .
- a second frequency derived from the 1064 nm beam is generated in the KTP crystal 22 . This beam travels along the path 26 a and is extracted from the resonator to supply an output beam along path 26 b.
- the output beam along path 26 b passes through a controllable attenuator 36 , a beam splitter 38 , which supplies a portion of the output beam to a surgical detector 40 , and a component group 42 as described in more detail below.
- the attenuator, detector, and component group are all coupled to a data processing system 34 , across lines 34 j , 34 k , and 34 p.
- the Q-switch 20 is controlled by Q-switch driver 21 , which is, in turn, coupled to data processor 34 across line 34 i .
- the Q-switch is an acoustic-optic Q-switch.
- the power supply 30 generates an electrical power signal for controlling the arc lamp 28 .
- This power signal is controlled by the data processor 34 across line 34 h and by drive circuitry 32 across line 32 a .
- Drive circuitry 32 a is controlled by the data processor across lines 34 a through 34 g .
- a sensor 57 is coupled with the data processor to sense an environmental condition, such as temperature or humidity, that affects operation of the laser system.
- a modem 56 is connected to the data processor 34 , providing an interface for remote access to memory in the data processor.
- a control panel 35 by which a user can supply input signals and parameters, is provided. This control panel 35 is connected to the data processor 34 across line 34 n.
- the non-linear crystal may be mounted outside the resonant cavity of the resonator. Also, it may be used for extracting outputs other than the second harmonic, such as sum-of-frequency derivation or the like.
- the wavelength used according to the present invention for BPH treatment should be strongly absorbed in the prostate tissue to help initiate and maintain tissue vaporization without creating deep tissue heating.
- the wavelength also must be minimally absorbed by the irrigant it used during the procedure, typically water.
- the 532 nm light produced by the system of FIG. 5 is both strongly absorbed in oxyhemoglobin and weakly absorbed in water. Oxyhemoglobin is readily present in prostate tissue and serves as an efficient chromophore for 532 nm light.
- the differential in absorption coefficients between oxyhemoglobin and water at 532 nm is approximately 5 orders of magnitude (10 5 ).
- wavelengths in the range from 200 nm-650 nm are used, which have strong oxyhemoglobin absorption and relatively weak water absorption (>10 2 ⁇ ). In yet other embodiments, wavelengths in the range from 200 nm to 650 nm range are used, which have strong oxyhemoglobin absorption and relatively weak water absorption (>10 ⁇ ).
- alternative pump power sources such as laser diode arrays, other lasers for longitudinal pumping, and others, can be used as suits the needs of a particular gain medium and application of the laser system.
- Representative laser diodes include laser diodes providing output in the range of 805 to 820 nm in wavelength with an input power to the array of pumping diodes in the range of 300 to 500 Watts.
- the laser diodes used for pump energy are operated in a modulated macro-pulse mode, or in a continuous mode, as suits a particular implementation.
- the laser systems shown in FIGS. 5 and 6 can be modified by removing both the Q-switch and the external surgical attenuator.
- the Q-switch and surgical attenuator are removed because the modulated pump power provides a great deal of flexibility in controlling the output power of the laser not attainable using a Q-switch.
- the data processing system can be programmed to maintain a constant thermal load in the laser system while varying the peak pump power widely.
- the peak current and duty cycle of the pump power source can be adjusted in such a way to keep the average pump power constant, but the second harmonic power during the ready and work modes adjusted by selecting the peak current and duty cycle.
- Attenuators may well be eliminated for the work mode.
- the average power does not have to be constant, rather it can be maintained at levels which keep thermal focusing of the gain medium within the range of stability of the resonator.
- a representative laser system adapted for delivery of energy as described above comprises an 80 watt average power, 532 nm output wavelength, solid state, intra-cavity frequency doubled Nd:YAG laser.
- an arc lamp pump source is modulated at a period of 4.5 ms with a 16 ms duty cycle, generating 285 watts peak macro-pulse power.
- An intra-cavity acousto-optic AO Q-switch is used to further modulate the energy at a period of 40 kHz with a 450 us micro-pulse.
- the laser energy is coupled to a side firing fiber optic delivery device for delivery to prostate tissue.
- the laser system uses a combination touch screen and control knob user interface to assist the operator in setting up the surgical parameters, including power levels and pulse sequence specifications.
- the average power setting is prominently displayed on the screen.
- Parameter adjustments are made by first activating (touching) the desired parameter box on the screen and then turning the knob.
- the laser system uses a secure card key interface to enable the laser.
- the system is transportable. The system offers convenient storage and a fiber delivery device pole.
- FIG. 7 An example of an endoscope, in particular a transurethral cystoscope, for use with the present invention is shown in FIG. 7 .
- the cystoscope has a distal end 200 and a proximal end 201 .
- the distal end 200 includes a tongue member 202 for pushing tissue away from a treatment area in the region 204 .
- Laser radiation is directed sideways from opening 206 in to the region 204 , by a side firing fiber optic component. Water or saline solution is delivered and removed from the treatment area via lumens in the probe.
- a viewing optic is also placed in the opening 206 , by which the surgeon is able to view the treatment area during the procedure.
- an input port 203 and an output port 205 for flow of the irrigant is provided on the proximal end 201 of the cystoscope. Also, a fiber port 207 is used for insertion and removal of the fiber optic delivering laser radiation to the treatment area.
- a light source connector 209 is used for supplying light to the treatment area for visualization.
- a telescope 211 which can be coupled to a video camera, or looked into directly, is also included on the representative cystoscope.
- the vaporization of prostate tissue using oxyhemoglobin as the primary chromophore is related to the incident power density, or irradiance, which can be expressed in Watts/cm 2 .
- the overall rate of prostate tissue vaporization is a function of the spot size, absorption depth, and the power density. A large spot with high power density, and rapid absorption is ideal to rapidly vaporize tissue. A high power light source is required to achieve a large spot, high power density treatment beam. Peak laser power, average laser power, beam quality, delivery device design and delivery device placement all affect the efficiency of vaporization.
- the BPH treatment procedure can be outlined as follows for one embodiment of the invention, using a laser system as described above with reference to FIG. 5 .
- the procedure causes minimal bleeding. Great outcomes are achieved for patients suffering BPH, including improved urine flow rate, improved post-void residual, and improved symptom scores on BPH tests.
- the procedure often achieves immediate obstruction relief, and post operative catheterization is not always required.
- a typical photoselective vaporization of the prostate PVP procedure will use the following steps:
- Subjects will be administered general, spinal or local (prostatic block & oral and topical anesthesia) anesthesia at the discretion of the Surgeon.
- the procedure is performed without the use of general anesthesia or spinal nerve blocks, using only local anesthesia such as any combination of intraurethral topical anesthesia such as lidocaine, either a periprostatic block or a perirectal block, oral and/or intravenous drugs such as Fentanyl or Demerol, chilled irrigant, and irrigant containing anesthesia.
- Vaporization will be performed with the Laserscope ADD (Angled Delivery Device) fiber, which is a 600 um bare fiber with a quartz capsule over the 70 degree lateral deflecting quartz element and a spot diameter of 1.2 mm at 2 mm.
- Laserscope ADD Angled Delivery Device
- the laser fiber will be introduced through the lumen of a standard 22 Fr continuous flow laser cystoscope, and sterile water will be used as the irrigant.
- KTP laser energy will be generated by a high power 532 nm laser capable of delivering 80 W of KTP laser power to tissue.
- the visible laser beam will be slowly moved along the length and breadth of the lateral lobe as the tissue is vaporized. The laser will be carefully directed toward the apical tissue making sure to protect the external sphincter.
- the median lobe will be vaporized evenly to the level. of the transverse fibers of the vesicle neck. If the median lobe is too large, then it should be partially vaporized before ablation of the lateral lobes to facilitate the movement of the scope and irrigation, and then the remainder will be flattened out later during the procedure.
- the end point of the procedure should be judged by the size and appearance of the large transurethral resection-like cavity and by the diminished efficacy of the vaporization effect at the prostatic capsule.
- the median and lateral hypertrophic tissue must be vaporized to the level-of the transverse fibers and any lingering loose fibers should be removed prior to completion of the treatment.
- the cystoscope is removed and, if necessary, a foley catheter is inserted at the physician's discretion.
- FIGS. 8 and 9 illustrate the different optical penetration depths of the 532 nm wavelength and 1064 nm wavelength used in prior art procedures. See, S. L. Jacques. Laser - tissue interaction. Photochemical, photothermal and photomechanical . Surg. Clin N. Am. 1992; 72(3):531-558.
- the optical penetration depth of the 1064 wavelength beam from Nd:YAG laser beam is about 10 mm, which is 13 times larger than the penetration depth of the second harmonic 532 wavelength laser beam, which is about 0.8 mm.
- the 1064 laser power is spread out over a much larger tissue volume than the power of the KTP laser. In case of the 1064 laser as shown in FIG. 9 , the temperature at the tissue surface barely reaches 100° C.
- the 532 laser beam in contrast, is substantially completely absorbed within less than about 1 mm of the surface of prostatic tissue.
- the laser power is confined to a very small tissue volume.
- the high volumetric power density results in a fast heating of the tissue and efficient tissue vaporization.
- Volumetric power density delivered to tissue is a function of the absorbtion depth, irradiance in Watts/cm 2 and spot size on the surface of the tissue.
- the coagulation zone is very thin because of the small optical penetration depth of the 532 wavelength, and because substantially all of the radiation is converted to vaporization rather than residual heat.
- wavelengths which are substantially completely absorbed within less than about 1 mm of the surface of the prostatic tissue include wavelengths less than about 650 nm, for example between about 200 nm and 650 nm.
- FIGS. 10 and 11 illustrate a profile of a beam delivered to tissue using one representative side firing optical fiber, to show spot size as a function of distance from the side of the optical fiber.
- FIG. 10 is an end view, showing a fiber 600 , cladding 601 on the fiber, an air space 602 , and a tip 603 through which the beam is directed by a reflecting face on the fiber.
- the cross-section of the beam is represented by the crossing lines 604 and 605 .
- the beam has a width in this dimension of about 0.35 mm at 1 mm from the side of the tip 603 . At about 2 mm from the side of the tip 603 , the width is about 1 mm. At about 3 mm distance from the side of the tip 603 , the beam width is about 2.2 mm.
- FIG. 11 is a side view, with like components given the same reference numbers.
- the beam width in this dimension is represented by lines 606 and 607 .
- the beam has a width in this dimension of about 0.7 mm at 1 mm from the side of the tip 603 .
- the width is about 1 mm.
- the beam width is about 1.5 mm.
- the spot size at 1 mm from the side of the tip is defined basically by an elipse having a major axis of 0.7 mm, and a minor axis of 0.35 mm.
- the area of the spot at 1 mm is around 0.2 mm 2 .
- the area of the spot is about 0.8 mm 2 .
- the spot size should be large enough that the operator can remove tissue at a reasonable rate, and see the results of a single pass of the spot over a region of tissue. If the spot size is too small, the rate of the operation is too slow. Also, if the spot size is too big, then the procedure is difficult to control precisely.
- a preferred spot size is less than about 1 mm 2 , and more particularly between about 0.8 mm 2 and about 0.05 mm 2 .
- Other apparatus may be used for delivery of the beam with the desired spot size, including embodiments without diverging beams, and embodiments with converging beams.
- the irradiance of the beam at 1 mm from the side of the tip for an 80 W average power laser as described above is about 30 kiloWatts/cm 2 .
- FIG. 12 shows, heuristically, how vaporization rate and coagulation rate depend on the volumetric power density.
- the vaporization rate (in mm/s) is defined as tissue depth that is vaporized per time interval.
- the coagulation rate (in mm/s) is defined as the depth of residual coagulated tissue that remains after a certain time of vaporization.
- vaporization threshold Below a certain volumetric power density, referred to as a “vaporization threshold” in FIG. 12 , no tissue gets vaporized. All laser energy stays inside the tissue. Tissue coagulation occurs where the tissue temperature rises above approximately 60° C. As the volumetric power density is increased a bigger and bigger tissue volume gets coagulated.
- the vaporization threshold At the vaporization threshold, vaporization starts. Above the vaporization threshold the vaporization rate can be considered to increase linearly with the volumetric power density for the purpose of understanding the present invention, and as described by a steady state model for continuous wave laser tissue ablation, known by those familiar with the art of laser-tissue interaction.
- VLAP visual laser ablation of the prostate
- Nd:YAG laser at 1064 nm
- Histology studies have shown that the 1064 nm laser induces deep coagulation in the tissue that results in edema and delayed tissue sloughing. This effect was described by Kuntzman, et al., High - power potassium titanylphosphate laser vaporization prostatectomy . Mayo Clin Proc 1998:73:798-801.
- the VLAP procedure is believed to lie around point 650 , barely above the vaporization threshold.
- the ablation rate further increases and the coagulation rate further drops, so that the procedure lies heuristically at point 652 in FIG. 12 .
- An 80 Watt KTP laser can be used to easily reach irradiance levels that vaporize substantially more tissue than is left as residual coagulation after the procedure. More precisely, the vaporization rate is substantially higher than the coagulation rate as given by the definition above, using high irradiance levels that are easily achieved with higher power lasers.
Landscapes
- Health & Medical Sciences (AREA)
- Surgery (AREA)
- Physics & Mathematics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Electromagnetism (AREA)
- Optics & Photonics (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Otolaryngology (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Laser Surgery Devices (AREA)
Abstract
Description
- This application is a continuation of co-pending U.S. patent application Ser. No. 11/191,197 filed on 27 Jul. 2005.
- application Ser. No. 11/191,197 is a continuation of application Ser. No. 10/278,723 filed on 23 Oct. 2002 (now U.S. Pat. No. 6,986,764 B2).
- application Ser. No. 10/278,723 is a continuation-in-part of U.S. patent application Ser. No. 09/737,721 filed 15 Dec. 2000 (now U.S. Pat. No. 6,554,824 B2).
- application Ser. No. 10/278,723 also claims the benefit of U.S. Provisional Application No. 60/336,481, filed 24 Oct. 2001.
- application Ser. No. 10/278,723 also claims the benefit of U.S. Provisional Application No. 60/338,728, filed 5 Nov. 2001; and application Ser. No. 10/278,723 also claims the benefit of U.S. Provisional Application No. 60/337,810, filed 5 Nov. 2001.
- 1. Field of the Invention
- The present invention relates generally to laser treatment of soft tissue, and more particularly to photoselective vaporization of the prostate PVP, and to photoselective vaporization of other tissue.
- 2. Description of Related Art
- Benign Prostatic Hyperplasia (BPH) is a condition wherein continued growth of the prostate restricts the passage of urine through the lower portion of the bladder and the urethra. BPH is often treated by surgically removing excess prostate tissue from the transitional zone of the prostate that is pressing on the urethra, which usually relieves the bladder outlet obstruction and incomplete emptying of the bladder caused by the BPH.
- Recently, the most commonly employed procedure for removal of excess prostate tissue has been transurethral resection of the prostate, also known as TURP. In the TURP procedure, the surgeon utilizes a standard electrical cutting loop to shave off small pieces of the targeted tissue from the interior of the prostate. At the end of the operation, pieces of excised prostate tissue are flushed out of the bladder using an irrigant.
- While effective, the TURP procedure is known to cause numerous side effects, including incontinence, impotence, retrograde ejaculation, prolonged bleeding and TUR syndrome. Recently, alternative procedures have been developed which reduce or avoid the side effects associated with TURP. One class of procedures involves “cooking” prostate tissue by heating it to a to a temperature above 45 degrees Celsius, causing tissue coagulation. Typically this is accomplished using electrically resistive elements such as: radio frequency (RF), microwave, or long-wavelength lasers. An example of a procedure of this nature is discussed in U.S. Pat. No. 6,064,914 by Trachtenberg (“Thermotherapy Method”). Because these procedures leave the thermally-treated tissue in place, post-procedure edema, dysuria, and retention rates are relatively high. Further, use of thermal procedures requires the patient to be catheterized for several days following the procedure, and may cause extensive and unpredictable scarring of the intra prostatic urethra.
- Another class of procedures involves vaporizing or ablating the targeted tissue using laser light. These procedures generally avoid the high infection rates and scarring problems of thermally-based procedures. However, laser ablation of prostate tissue has to date, required the use of an expensive laser capable of generating high-power laser light. The high cost of purchasing or leasing such a laser results in a concomitant increase in the cost of the procedure. Finally, the ablation process typically occurs slowly, resulting in a lengthy procedure time.
- The Ho:YAG laser and its fiberoptic delivery system is an example of a laser that is commonly used for ablating prostate tissue. The Ho:YAG laser generates pulses of 2100 nm light that are strongly absorbed by water in the prostate tissue and in the saline irrigant positioned between the distal end if the fiberoptic and the tissue. The absorption coefficient of water is so high at 2100 nm that 50% of the light is absorbed within 0.2 mm of water. Consequently even a thin layer of irrigant positioned between the distal end on the fiberoptic and the tissue will absorb a large fraction of the laser light. Furthermore with the short pulse durations (Tp<0.5 ms) and large pulse energies (Ep>1.0 joule) used for ablating prostate tissue the irrigant is explosively boiled creating a shock wave that tears tissue. Because water is such a large constituent of prostate tissue and blood, there is essentially no selective absorption by blood. This combination of violent tissue disruption and the superficial unselective light penetration leads to poor hemostasis.
- Nd:YAG lasers operating at 1064 nm have also been used for ablating prostate tissue. Although 1064 nm light is hemostatic at high power levels its low absorption in blood and prostate tissue leads to inefficient ablation and a large residual layer of thermally denatured tissue several millimeters thick. After surgery, the coagulated, thermally denatured tissue swells and leads to transient urinary retention, which can cause long catheterization times, painful urination, and high infection rates.
- Frequency doubled Nd:YAG lasers operating at 532 nm in a Quasi continuous mode at power levels up to 60 watts have been used to efficiently and hemostatically ablate prostate tissue. These lasers are pumped by CW krypton arc lamps and produce a constant train of Q-switched pulses at 25 kHz. The high Q-Switch frequency makes the tissue effects indistinguishable from CW lasers of the same average power. The 532 nm light from these lasers is selectively absorbed by blood leading to good hemostasis. When ablative power densities are used, a superficial layer of denatured prostate tissue less than 1 mm is left behind. This thin layer of denatured tissue is thin enough that the immediate post surgical swelling associated with other treatment modalities is greatly reduced. This reduced swelling leads to short catheterization times and less dysuria. At high powers, 532 nm lasers induce a superficial char layer (an absorptive, denatured layer) that strongly absorbs the laser light and greatly improves the ablation efficiency. The problem with the existing 532 nm lasers used to date is that they are large, expensive, inefficient, and have a highly multi-mode output beam that makes them inefficient for ablating prostate tissue. Furthermore, residual coagulation of tissue due to the procedure remains significant using the techniques known in the prior art, as discussed below.
- High power densities are required for rapid and efficient vaporization of prostate tissue. The difficulty of achieving higher average output power densities is that when high input powers are supplied to the laser element from an excitation source such as an arclamp a large amount of heat is generated in the lasing element. This heat induces various deleterious effects in the lasing element. In particular the temperature difference between the coolant and the hot lasing element generates a thermally induced graded index lens that decreases the beam quality of the laser and causes the laser to operate with more transverse optical modes than it would otherwise.
- The M2 parameter is a well established convention for defining the beam quality of a laser and is discussed in pages 480-482 of Orazio Svelto and David C. Hanna, Principles of Lasers, Plenum Press, New York, 1998, which is incorporated herein by reference. The beam quality measures the degree to which the intensity distribution is Gaussian. The quantity M2 is sometimes called inverse beam quality rather than beam quality but in this application it will be referred to as beam quality. M2 is defined as
- where π refers to the number 3.14 . . . , σ is used to represent the spot size, the subscripts x and f represent the spatial and frequency domains along the x-axis, respectively, and the subscripts G and NG signify Gaussian and non-Gaussian, respectively. The x-axis is transverse to the direction of propagation of the beam. The beam quality in any direction transverse to the beam may be essentially the same. Therefore the subscript x is dropped from the M2 elsewhere in the specification. The beam widths or us are determined based on the standard deviation of the position, where the squared deviation of each position is weighted by the intensity at that point. The beam width in the frequency domain σf is the beam width of the beam after being Fourier transformed.
- The formula usually used for calculating the angular divergence, θ, of a beam of light of wavelength λ is strictly valid only for a beam having a Gaussian intensity distribution. The concept of beam quality facilitates the derivation of the angular divergence, θ, for the beam with a non-Gaussian intensity distribution, according to
- For example, a TEM00 laser beam has a high beam quality with an M2 of 1, whereas by comparison, high power surgical lasers operate with M2 values greater than 100.
- The Applicants have recognized that high power lasers typically have an M2>144. The larger number of modes makes M2 larger and makes it difficult to focus the light into small, low numerical aperture fibers and reduces the ability to project high power density light onto tissue. As a result, the vaporization efficiency of CW arclamp pumped 532 nm lasers on prostate tissue is significantly reduced.
- Other aspects and advantages of the present invention can be seen on review of the drawings, the detailed description and the claims, which follow.
- Photoselective vaporization of tissue, such as the prostate for treatment of BPH, is based upon applying a high intensity radiation to prostate tissue using a radiation that is highly absorptive in the tissue, while being absorbed only to a negligible degree by water or other irrigant during the operation, at power densities such that the majority of the energy is converted to vaporization of the tissue without significant residual coagulation of adjacent tissue. Unlike prior art techniques for treatment of BPH, the procedure may be conducted under local anesthesia, and patients are usually able to go home a couple of hours after the procedure. The procedure results in fewer side effects than prior art techniques, including lower incidence of dysuria and hemouria. Patients may be treated without requiring post-operative catherization of the urethra.
- According to one embodiment of the invention, a method for treating BPH comprises the steps of providing a solid-state laser having a laser element positioned to receive pump radiation from an excitation source; in some cases modulating the source to cause the laser to emit pulsed laser light; and delivering the laser light to targeted tissue. Various solid-state lasers may be used for this purpose, including (without limitation), a Q-switched laser using a frequency doubling crystal such as potassium-titanyl-phosphate (KTP), pumped using a diode array, an arc lamp or a flash lamp. While Q-switching induces short, “micro-pulses,” a “macro-pulse” duration of the laser light is preferably in the range of 0.1 to 500 milliseconds, induced by for example modulating the pump energy with the desired macro-pulse length. The wavelength of the laser light is preferably between 200 and 1000 nm. The laser light is preferably delivered to the targeted prostate tissue through an optical fiber terminating at or near a distal end in a side-firing probe. However the side-firing probe is not essential.
- Operation of the solid-state laser in a “macro-pulsed” mode is more efficient in inducing rapid tissue ablation than a CW laser of the same average power. This is in part because the macro-pulsing is more efficient in inducing “char” formation, a mild carbonization in which the tissue typically darkens slightly but does not necessarily turn completely black. Although char formation is not essential to efficient rapid ablation it is helpful because the darkened tissue is better at absorbing light. The macro-pulsed laser is also more efficient and has higher beam quality, with M2 values typically less than 144, than a continuous wave laser with same average output power.
- According to a second embodiment of the invention, a method for treating soft tissue comprises the steps of providing a solid-state laser having a laser element positioned to receive pump radiation from a pump radiation source; modulating the pump radiation source to cause the laser element to emit laser light having a pulse duration of between 0.1 milliseconds and 500 milliseconds and an output power exceeding 20 watts; and delivering the laser light to targeted tissue.
- According to a third embodiment of the invention, a method for treating BPH comprises the steps of providing a solid-state laser having a laser element positioned to receive pump radiation from a pump radiation source; Q-switching the laser to generate a quasi-continuous wave (CW) beam having an output power exceeding 60 watts; and, delivering the beam to targeted prostate tissue.
- According to a fourth embodiment of the invention, a method for treating BPH comprises the steps of providing a solid-state laser having a laser element positioned to receive pump radiation from a pump radiation source such as a laser diode; Q-switching the laser to generate a quasi-continuous wave (CW) beam having an output power exceeding 20 watts with an M2 less than 144; and delivering the beam to prostate tissue.
- It has been recognized that as more and more laser energy is consumed by vaporization of the tissue, the amount of laser energy leading to residual tissue coagulation gets smaller, i.e. the amount of residual coagulation drops, and the side effects attendant to the residual injury caused by the surgery drop dramatically. Thus, the extent of the zone of thermal damage characterized by tissue coagulation left after the procedure gets smaller with increasing volumetric power density, while the rate of vaporization increases. Substantial and surprising improvement in results is achieved. It has been recognized that increasing the volumetric power density absorbed in the tissue to be ablated, has the result of decreasing the extent of residual injury of the surrounding tissue. This recognition leads to the use of higher power laser systems, with greater levels of irradiance at the treatment area on the tissue, while achieving the lower levels of adverse side effects and a quicker operation times.
- Although the invention can be generalized other types of tissue, one embodiment of the invention provides a method for photoselective vaporization of prostate tissue. According to this embodiment, the method includes delivering laser radiation to the treatment area on the tissue, via an optical fiber for example, wherein the laser radiation has a wavelength and irradiance in the treatment area on the surface of the tissue sufficient because vaporization of a substantially greater volume of tissue than a volume of residual coagulated tissue caused by the laser radiation. In one embodiment, the laser radiation is generated using a neodymium doped solid-state laser, including optics producing a second or higher harmonic output with greater than 60 watts average output power, and for example 80 watts average output power, or more. The laser radiation is coupled into an optical fiber adapted to direct laser radiation from the fiber to the treatment area on the surface of the tissue. For the treatment of prostate, the fiber optic is inserted via transurethral cystoscope, including lumens for delivering irrigants to the treatment area, and for direct visualization during the treatment.
- In other embodiments, the delivered laser radiation has a wavelength in a range of about 200 nm to about 650 nm, and has an average irradiance in the treatment area greater than about 10 kilowatts/cm2, in a spot size of at least 0.05 mm2. More preferably, the irradiance is greater than about 20 kilowatts/cm2, and even more preferably greater than about 30 kilowatts/cm2. The spot size in preferred systems is for example less than about 0.8 mm2.
- Accordingly, in one embodiment, the second harmonic output of the neodymium dope solid-state laser is applied using a side firing tip on the optical fiber. The side firing tip, which causes a diverging beam to be directed out of the optical fiber, is placed close to the tissue, within about 1 mm from the side of the side firing tip to contacting the side of the tip. Close placement increases the irradiance delivered to the treatment area so that higher irradiance is available with solid-state lasers generating a 60 to 80 watts average output power.
- According to the present invention, the efficiency of the vaporization and the reduction of injury to residual tissue are sufficient that the procedure may be carried out while applying only local anesthetic during the delivery of laser energy, and throughout the procedure. For example, a procedure according to the present invention includes applying intraurethral topical anesthesia such as lidocaine, either a periprostatic block or a perirectal block, oral and/or intravenous drugs such as Fentanyl or Demerol, chilled irrigant, and irrigant containing anesthesia.
- Furthermore, embodiments of the invention include the delivery of the laser energy using a Q-switched, solid-state laser which produces micro-pulses in combination with applying pump power to the laser medium in a sequence a pulses so that output radiation is produced in macro-pulses having a peak power of greater than 200 watts, and more preferably about 240 watts or greater. The peak irradiance in the treatment area during the pulses is thereby substantially increased, and preferably greater than 50 kilowatts/cm2, and as much as 90 kilowatts/cm2 in some embodiments of the invention.
- Other aspects and advantages of the present invention can be seen on review the figures, the detailed description, and the claims which follow.
-
FIG. 1 depicts a laser system for implementing the tissue ablation methods of the invention; -
FIG. 2 depicts a side-firing probe for use with the system ofFIG. 1 ; -
FIG. 3 depicts an exemplary output waveform of theFIG. 1 laser when the laser is operated in a macro-pulsed mode; and -
FIG. 4 depicts an exemplary output waveform of theFIG. 1 laser when the laser is operated in a quasi-CW mode. -
FIG. 5 is a block diagram of a laser system adaptable for use according to the present invention. -
FIG. 6 is a block diagram of an alternative laser system adaptable for use according to the present invention. -
FIG. 7 is a diagram of a transurethral cystoscope, adaptable for use according to the present invention. -
FIG. 8 illustrates absorption depth in prostate tissue for 532 nm light. -
FIG. 9 illustrates absorption depth in prostate tissue for 1064 nm light. -
FIG. 10 is a diagram of a beam path from an end view of a side firing tip, according to one embodiment of the present invention. -
FIG. 11 is a diagram of a beam path from a side view of the side firing tip ofFIG. 10 , according to one embodiment of the present invention. -
FIG. 12 is a heuristic diagram illustrating operation of the present invention. -
FIG. 1 is a block diagram depicting anexemplary laser system 100 which may be employed for implementing the present invention.Laser system 100 includes a solid-state laser 102, which is used to generate laser light for delivery throughoptical fiber 106 to targettissue 104. As will be discussed in further detail herein below,laser 102 is capable of being operated in a “macro-pulsed” mode, wherein the laser light is emitted as macro-pulses having relatively long pulse durations. -
Laser 102 more specifically comprises alaser element assembly 110, pumpsource 112, andfrequency doubling crystal 122. In the preferred embodiment,laser element 110outputs 1064 nm light which is focused intofrequency doubling crystal 122 to create 532 nm light. According to one implementation,laser element assembly 110 may be neodymium doped YAG (Nd:YAG) crystal, which emits light having a wavelength of 1064 nm (infrared light) when excited bypump source 112.Laser element 110 may alternatively be fabricated from any suitable material wherein transition and lanthanide metal ions are disposed within a crystalline host (such as YAG, Lithium Yttrium Fluoride, Sapphire, Alexandrite, Spinel, Yttrium Orthoaluminate, Potassium Gadolinium Tungstate, Yttrium Orthovandate, or Lanthanum Scandium Borate).Laser element 110 is positioned proximal to pumpsource 112 and may be arranged in parallel relation therewith, although other geometries and configurations may be employed. - Pump
source 112 may be any device or apparatus operable to excitelaser element assembly 110. Non-limiting examples of devices which may be used aspump source 112, include: arc lamps, flashlamps, and laser diodes. - A Q-
switch 114 disposed withinlaser 102 may be operated in a repetitive mode to cause a train of micro-pulses to be generated bylaser 102. Typically the micro-pulses are less than 1 microsecond in duration separated by about 40 microseconds, creating a quasi-continuous wave train. Q-switch 114 is preferably of the acousto-optic type, but may alternatively comprise a mechanical device such as a rotating prism or aperture, an electro-optical device, or a saturable absorber. -
Laser 102 is provided with acontrol system 116 for controlling and operatinglaser 102.Control system 116 will typically include a control processor which receives input from user controls (including but not limited to a beam on/off control, a beam power control, and a pulse duration control) and processes the input to accordingly generate output signals for adjusting characteristics of the output beam to match the user inputted values or conditions. With respect to pulse duration adjustment,control system 116 applies an output signal to a power supply (not shown) drivingpump source 112 which modulates the energy supplied thereto, in turn controlling the pulse duration of the output beam. - Although
FIG. 1 shows an internal frequency doubled laser, it is only by way of example. The infrared light can be internally or externally frequency doubled using non-linear crystals such as KTP, Lithium Triborate (LBO), or Beta Barium Borate (BBO) to produce second harmonic 532 nm green light, and higher harmonics. The frequency doubled, 532 nm wavelength and the shorter wavelength higher harmonic beams are better absorbed by the tissue, and promote more efficient tissue ablation. - In one preferred embodiment the resonant cavity control system is that described in U.S. Pat. No. 5,151,909, which is incorporated by reference as if fully set forth herein.
-
Laser 102 further includes an output port couplable tooptical fiber 106.Output port 118 directs the light generated bylaser 102 intooptical fiber 106 for delivery totissue 104.Mirrors lasing element 110 to thefrequency doubling crystal 122, in addition to forming the resonant cavity of the laser.Mirrors frequency doubling crystal 122 on the side closer to mirror 130, and to compensate for thermal lensing in the lasing element. Althoughmirrors Mirrors Mirror 126 only reflects the light originating from the lasing element 110 (e.g. 1064 nm) but is transparent to the frequency doubled light (e.g. 532 nm), forming an output window. Higher harmonic outputs may also be generated from the 1064 nm line, or other line amplified in the laser, including third and fourth harmonics, for shorter wavelengths. Other laser systems may be used, including but not limited to Sapphire lasers, diode lasers, and dye lasers, which are adapted to provide the output power and wavelengths described herein, including wavelengths in the ranges from 200 nm to 1000 nm and from 1100 nm to 1800 nm, for example. - While a bare fiber may be utilized for certain procedures,
optical fiber 106 preferably terminates in atip 140 having optical elements for shaping and/or orienting the beam emitted byoptical fiber 106 so as to optimize the tissue ablation process. -
FIG. 2 depicts a side-firingprobe tip 200, which may be used as tip 140 (FIG. 1 ). Thetip 140 is treated to deflect light sideways. Some examples of methods for deflecting the light sideways are to include a light scattering material in thetip 140 and/or to place a reflective element in thetip 140. The reflective element could be angled at 45°, for example; to deflect the light at 90° with respect to the axis of thefiber 106. Side-firingprobe tip 200 includes an opticallytransparent sleeve 202 having a transparent window 204 (which may be constructed as a cutout in the wall ofsleeve 202 through which the beam is emitted in a direction transverse to the optical axis offiber 106.) An acceptable range of angles in which to deflect the light beam is between about 40 to 120 degrees with respect to the axis of the fiber. The preferred embodiments use an angle of either 70 or 100. The angle of 80° is preferred from the standpoint of the ease in manufacturing thetip 200 and the angle of 90° is preferred from the standpoint of the ease in aiming the side firing light. - In a typical mode of operation,
optical fiber 106 is held within an endoscope such as a cystoscope or similar instrument that allows the clinician to precisely position the distal end of the optical fiber adjacent to the targeted tissue. The endoscope also has channels for supplying and removing an irrigant solution to and from the tissue. In addition, light and image guides are also included for illuminating and imaging the tissue so that the clinician may direct the laser light and assess the progress and efficacy of the ablation procedure. -
FIG. 3 illustrates an exemplary output waveform applied totissue 104 whenlaser 102 is operated in the macro-pulsed mode. Each macro-pulse 302 is defined by a train of Q-switched micro-pulses 304. While a relatively small number ofmicro-pulses 302 are depicted for purposes of clarity, an actual macro-pulse may comprise hundreds or thousands ofcomponent micro-pulses 304. In the preferred embodiment there are between 2 and 12,200 micro-pulses per macro-pulse. - An arc lamp, for example, when used as the
pump source 112, is kept at a low power level between pulses that are preferably just enough to maintain the arc. These low pump powers are below the lasing threshold of the laser; as a consequence, there is no laser output between macro-pulses. - As mentioned above, the pulse duration or width D (
FIG. 3 ) of the output beam is governed by the modulation ofpump source 112, and more specifically by the period during which thepump source 112 is maintained in an “on” or high-power condition. In other words, the longer thepump source 112 is maintained in an on condition, the longer the pulse width. Typically,laser 102 will be capable of deliveringpulses 302 having pulse durations D in the range of 1 to 20 milliseconds (2 to 490 micro-pulses) or 1 to 50 milliseconds (2 to 1,220 micro-pulses) and average output powers preferably exceeding 60 watts and preferably up to 100 or 200 watts. The ratio of D to the period of the macro-pulses defines the duty cycle, which is typically between 10 and 50%. - In accordance with one embodiment of the invention, a
laser system 100 of the foregoing description is employed to treat BPH by ablating targetedprostate tissue 104. The clinician may utilize an endoscope or similar instrument to guide the distal end and tip 140 ofoptical fiber 106 into alignment with the targetedprostate tissue 104.Laser system 100 is then operated in the macro-pulsed mode so thatlaser 102 generates laser light having the pulsed waveform depicted inFIG. 3 and delivers it throughoptical fiber 106 totissue 104. - It is known that irradiation of
prostate tissue 104 may initially cause tissue heating resulting in the formation of a char layer. This char layer is highly optically absorptive in the wavelengths emitted bylaser 102, which thereby facilitates efficient absorption of the laser light and resultant ablation oftissue 104. However, the formation of the char layer is not essential for efficient ablation. Prior art techniques for treatment of BPH by laser ablation (such as the technique described by Kuntzman et al. in “High-Power (60-Watt) Potassium-Titanyl-Phosphate Laser Vaporization Prostatectomy in Living Canines and in Human and Canine Cadavers,” Urology, Vol. 49, No. 5 (1997)) utilized a quasi-CW laser to irradiate the prostate. Although such lasers do produce moderately high average powers, they have a large number of transverse modes and as such, produce highly divergent light when focused into small fiberoptics. This leads to less than optimal power densities when the laser light is directed at tissue. As a consequence, these lasers are not particularly efficient at inducing formation of a char layer, and ablation rates are relatively slow, significantly lengthening procedure times. Further, since formation of the char layer takes place at relatively low rates, undesirable thermal damage to deeper tissue layers may occur. In contrast, it has been found that a macro-pulsed beam, such as that generated bylaser 102, promotes rapid formation of a char layer even at moderate output energy levels, thereby helping to accelerate ablation rates and reducing procedure time. - The macropulsing can also increase efficiency because the threshold voltage required for lasing while macropulsing (the operating threshold) is lower than the initial threshold voltage for lasing (cold threshold).
- Macropulsing is also more efficient for producing green light because the conversion of infrared light to frequency doubled light increases as the square of the infrared light intensity. The higher peak powers of the macro-pulsed infrared light leads to higher second harmonic conversion efficiency. For example, at any given time, the input power and output power of a frequency-doubled laser using KTP are related according to
Po=A(Pi)2, - Where A is an experimentally determined positive constant. This equation relates the peak input power to the peak output power. However, the average input power and output power for a duty cycle of k percent are given by
<Pi>=k(Pi) and
<Po>=k(Po)=kA(Pi)2 =A(<Pi>)2 /k,
where the brackets “< >” indicate an average value of the enclosed quantity. Thus, decreasing the duty cycle from 100% to 50% (i.e. reducing k from 1 to 0.5) while simultaneously doubling the peak input power Pi results in no change to the average input power <Pi> and a doubling of the average output power <Po>. Pulse modulating or macropulsing using Q-switching, for example, enables reaching higher average output powers with less thermal lensing due to the lower input power. - Additionally, it is possible that the frequency doubling crystal has nonlinearly increasing output power as a function of the input power. In other words the second derivative of the output power with respect to the input power may be positive, in which case the rate of increase of the output power increases with increasing input power. Specifically, in such a case the functional dependence of the instantaneous or peak output power, Po, on the instantaneous or peak input power, Pi, is such that
d 2(Po)/d(Pi)2>0.
When this is true, and Po is an increasing function of Pi, the higher peak input power results in a more efficient laser because ratio of the output to input power increases. - Pump source modulation of the laser can produce high peak power macro-pulses and affect the efficiency of the average power output. Macro-pulse in excess of a steady state power can substantially improve the initiation of the vaporization of prostate tissue. The higher peak power of the macro-pulse rapidly initiates charring which in turn serves as an additional chromophore for the incident energy and enhances the vaporization rate. A 30% macro-pulse duty cycle is sufficient to increase the average power output of an arc lamp pumped laser to greater than 80 watts. Additionally the pump modulation generates macro-pulse with pulse powers greater than 240 watts.
- By way of a non-limiting example,
prostate tissue 104 may be efficiently and rapidly ablated whenlaser 102 is operated at an output power of 80 to 100 watts, a pulse duration of 1-50 milliseconds, and a wavelength of 532 nm. - In accordance with a second method embodiment of the invention,
laser system 100 may be utilized to ablate other types oftissue 104. Treatment oftissue 104 is performed in a manner substantially identical to the technique for treating BPH disclosed above. The clinician may utilize an endoscope or similar instrument to guide the distal end and tip 140 ofoptical fiber 106 into alignment with theprostate tissue 104.Laser system 100 is then operated in the macro-pulsed mode so that laser light having the pulsed waveform depicted inFIG. 3 is generated bylaser 102 and delivered throughoptical fiber 106 totissue 104. To achieve adequate results,laser system 100 is adjusted to emit a beam having a pulse duration between 0.1 and 500 milliseconds, and an output power of at least 20 watts. Upon vaporization of the required volume oftissue 104, (which may be assessed via an imaging channel contained in the endoscope), the output beam oflaser 102 is turned off. - In a third method embodiment of the invention, treatment of BPH is effected by operating
laser 102 in a quasi-CW mode at an output power greater than 60 watts. The increased denaturization of the tissue is dramatic with increases in power, suggesting a threshold effect. As depicted inFIG. 4 ,laser 102 generates a continuous train of Q-switchedmicro-pulses 400 when operated in quasi-CW mode. The laser light is then delivered viaoptical fiber 106 to targetedtissue 104. Operation in a quasi-CW mode at powers above 60 watts facilitates formation of char and consequent rapid ablation rates, whereas operation in a quasi-CW mode at powers below 60 watts forms char more slowly and causes more thermal damage to underling tissue. - A fourth embodiment of this invention is to produce a high power, high beam quality laser that can project high power density laser light onto tissue. To do this the number of transverse optical modes supported by the resonator needs to be kept as low as possible.
- Small M2 and high average powers can be achieved by reducing the degree of thermal lensing in the laser element. Using laser diodes as the excitation source is one effective way of greatly reducing both the size of the lasing element and the thermal gradient responsible for creating the thermal lens. The reason for this is that while 2-10% of the light produced from a flashlamp or arc lamp is converted into useful laser light 30-60% of the light emitted from laser diodes can be converted to laser light. Since the energy that is not converted to laser light is converted into heat, laser diodes deposit significantly less heat in the lasing element and as a consequence create a less powerful thermal lens. In this manner laser diodes can be used to pump crystalline laser elements or fiber lasers to produce high beam quality lasers. Slab and waveguide lasers that can be pumped by laser diodes, arc lamps, or flashlamps are another method of creating low M2 lasers. This is because the thermal gradient produced in slab lasers is linear across the thin dimension of the slab and not radially dependent in contrast to a typical cylindrical lasing element. The linear thermal gradient does not produce a thermal lens resulting in low M2 values.
- For example, as a result of the low M2 some embodiments of this invention are capable producing laser light that upon exiting a flat end of a fiber having a diameter of 600 μm has a divergence of 15.3° or lower; 15° or lower; 10° or lower; or 5° or lower, and the power density can be 13,400 watts per cm2, or greater.
-
FIG. 5 shows a block diagram of a preferred laser system according to the present invention. InFIG. 5 , a laser resonator is defined byend mirror 10, turning mirrors 12 and 14, and endmirror 16. All of these mirrors are high reflecting (greater than 99.8%) at the 1064 nm line. Anoptical path 24 is defined by these mirrors. Again medium 18 comprising a Nd:YAG rod is mounted along the optical path within alamp housing 29. Anarc lamp 28 is also mounted within the housing and supplies pump power to the gain medium in response to current generated inpower supply 30. Also in theoptical path 24 is a Q-switch 20 between thelamp housing 29 and the turningmirror 12. Anon-linear crystal 22 is mounted between the turningmirror 14 and theback mirror 16. This non-linear crystal is preferably a KTP crystal aligned for frequency doubling to generate a 532 nm beam.Mirrors mirror 12 is transmissive and operates as an output coupler for the 532 nm beam. - Thus, the laser resonator is designed for resonating at a first frequency, i.e., 1064 nm along the Z-shaped
optical path 24. A second frequency derived from the 1064 nm beam is generated in theKTP crystal 22. This beam travels along thepath 26 a and is extracted from the resonator to supply an output beam alongpath 26 b. - The output beam along
path 26 b passes through acontrollable attenuator 36, abeam splitter 38, which supplies a portion of the output beam to asurgical detector 40, and acomponent group 42 as described in more detail below. The attenuator, detector, and component group are all coupled to adata processing system 34, acrosslines 34 j, 34 k, and 34 p. - The Q-
switch 20 is controlled by Q-switch driver 21, which is, in turn, coupled todata processor 34 across line 34 i. In the preferred system, the Q-switch is an acoustic-optic Q-switch. - Similarly, the
power supply 30 generates an electrical power signal for controlling thearc lamp 28. This power signal is controlled by thedata processor 34 acrossline 34 h and bydrive circuitry 32 acrossline 32 a.Drive circuitry 32 a is controlled by the data processor acrosslines 34 a through 34 g. Asensor 57 is coupled with the data processor to sense an environmental condition, such as temperature or humidity, that affects operation of the laser system. Amodem 56 is connected to thedata processor 34, providing an interface for remote access to memory in the data processor. Finally, acontrol panel 35, by which a user can supply input signals and parameters, is provided. Thiscontrol panel 35 is connected to thedata processor 34 acrossline 34 n. - In alternative systems, the non-linear crystal may be mounted outside the resonant cavity of the resonator. Also, it may be used for extracting outputs other than the second harmonic, such as sum-of-frequency derivation or the like.
- The wavelength used according to the present invention for BPH treatment should be strongly absorbed in the prostate tissue to help initiate and maintain tissue vaporization without creating deep tissue heating. The wavelength also must be minimally absorbed by the irrigant it used during the procedure, typically water. The 532 nm light produced by the system of
FIG. 5 , is both strongly absorbed in oxyhemoglobin and weakly absorbed in water. Oxyhemoglobin is readily present in prostate tissue and serves as an efficient chromophore for 532 nm light. The differential in absorption coefficients between oxyhemoglobin and water at 532 nm is approximately 5 orders of magnitude (105). In other embodiments, wavelengths in the range from 200 nm-650 nm are used, which have strong oxyhemoglobin absorption and relatively weak water absorption (>102×). In yet other embodiments, wavelengths in the range from 200 nm to 650 nm range are used, which have strong oxyhemoglobin absorption and relatively weak water absorption (>10×). - Of course, as shown in
FIG. 6 , in which like components have the same reference numerals as inFIG. 5 , alternative pump power sources, such as laser diode arrays, other lasers for longitudinal pumping, and others, can be used as suits the needs of a particular gain medium and application of the laser system. Representative laser diodes include laser diodes providing output in the range of 805 to 820 nm in wavelength with an input power to the array of pumping diodes in the range of 300 to 500 Watts. The laser diodes used for pump energy are operated in a modulated macro-pulse mode, or in a continuous mode, as suits a particular implementation. - The laser systems shown in
FIGS. 5 and 6 can be modified by removing both the Q-switch and the external surgical attenuator. The Q-switch and surgical attenuator are removed because the modulated pump power provides a great deal of flexibility in controlling the output power of the laser not attainable using a Q-switch. The data processing system can be programmed to maintain a constant thermal load in the laser system while varying the peak pump power widely. Thus, the peak current and duty cycle of the pump power source can be adjusted in such a way to keep the average pump power constant, but the second harmonic power during the ready and work modes adjusted by selecting the peak current and duty cycle. Although it may be necessary to use attenuators in the beamline during the ready mode in order to extract an aim beam, such attenuators may well be eliminated for the work mode. The average power does not have to be constant, rather it can be maintained at levels which keep thermal focusing of the gain medium within the range of stability of the resonator. - A representative laser system adapted for delivery of energy as described above, comprises an 80 watt average power, 532 nm output wavelength, solid state, intra-cavity frequency doubled Nd:YAG laser. To obtain optimal efficiency, an arc lamp pump source is modulated at a period of 4.5 ms with a 16 ms duty cycle, generating 285 watts peak macro-pulse power. An intra-cavity acousto-optic AO Q-switch is used to further modulate the energy at a period of 40 kHz with a 450 us micro-pulse. The laser energy is coupled to a side firing fiber optic delivery device for delivery to prostate tissue.
- The laser system uses a combination touch screen and control knob user interface to assist the operator in setting up the surgical parameters, including power levels and pulse sequence specifications. The average power setting is prominently displayed on the screen. Parameter adjustments are made by first activating (touching) the desired parameter box on the screen and then turning the knob. The laser system uses a secure card key interface to enable the laser. The system is transportable. The system offers convenient storage and a fiber delivery device pole.
- An example of an endoscope, in particular a transurethral cystoscope, for use with the present invention is shown in
FIG. 7 . The cystoscope has adistal end 200 and aproximal end 201. Thedistal end 200 includes atongue member 202 for pushing tissue away from a treatment area in theregion 204. Laser radiation is directed sideways from opening 206 in to theregion 204, by a side firing fiber optic component. Water or saline solution is delivered and removed from the treatment area via lumens in the probe. A viewing optic is also placed in theopening 206, by which the surgeon is able to view the treatment area during the procedure. On theproximal end 201 of the cystoscope, aninput port 203 and anoutput port 205 for flow of the irrigant is provided. Also, afiber port 207 is used for insertion and removal of the fiber optic delivering laser radiation to the treatment area. Alight source connector 209 is used for supplying light to the treatment area for visualization. Atelescope 211, which can be coupled to a video camera, or looked into directly, is also included on the representative cystoscope. - The vaporization of prostate tissue using oxyhemoglobin as the primary chromophore is related to the incident power density, or irradiance, which can be expressed in Watts/cm2. The overall rate of prostate tissue vaporization is a function of the spot size, absorption depth, and the power density. A large spot with high power density, and rapid absorption is ideal to rapidly vaporize tissue. A high power light source is required to achieve a large spot, high power density treatment beam. Peak laser power, average laser power, beam quality, delivery device design and delivery device placement all affect the efficiency of vaporization. A treatment beam 28.5 Kw/cm2 average irradiance with a 85.5 Kw/cm2 peak irradiance macro-pulse, with a spot size between about 0.2 and 0.5 mm2, rapidly vaporizes tissue.
- The BPH treatment procedure can be outlined as follows for one embodiment of the invention, using a laser system as described above with reference to
FIG. 5 . - Equipment/Set-up
-
- 21-24 french continuous flow cystoscope
- Laser
- Side firing probe
- Filter (eye safety filter for the monocular or the video camera)
- Sterile water
- Cystoscope eye piece or video system for direct visualization
- Anesthesia
-
- Any of the following or combinations of the following: General, spinal nerve block, topical, periprostatic block, perirectal block, pudental block & intervenous drugs
- This procedure does not require general or spinal anesthesia
- Technique/Process
- Prep patient following standard protocol for cystoscopic procedures
-
- Administer anesthesia
- Dilate the urethra
- Insert cystoscope
- Insert side firing delivery device
- Begin flow of sterile water
- Cystoscopy to assess gland
- Position fiber near tissue to be removed and active the laser
- Use a sweeping motion to vaporize desired tissue
- Continue vaporization until the capsule is reached
- Monitor vaporization efficiency, remove and clean fiber as required
- Debulk desired lobes, median & lateral lobes
- Fill bladder with water, remove cystoscope, observe discharge
- If necessary insert foley catheter
- The rapid vaporization with thin coagulation zone contribute to the hemostasis during the procedure. Because of minimal thermal damage to existing tissue, there is a low incidence of side effects, making such symptoms as Dysuria, Incontinence and Impotence which often occur in prior art techniques, very unlikely.
- Further, the procedure causes minimal bleeding. Great outcomes are achieved for patients suffering BPH, including improved urine flow rate, improved post-void residual, and improved symptom scores on BPH tests. The procedure often achieves immediate obstruction relief, and post operative catheterization is not always required.
- A typical photoselective vaporization of the prostate PVP procedure will use the following steps:
- A. At the investigator discretion, van buren sound the urethra in a standard fashion prior to insertion of the continuous flow cystoscope.
- B. Subjects will be administered general, spinal or local (prostatic block & oral and topical anesthesia) anesthesia at the discretion of the Surgeon. In some embodiments, the procedure is performed without the use of general anesthesia or spinal nerve blocks, using only local anesthesia such as any combination of intraurethral topical anesthesia such as lidocaine, either a periprostatic block or a perirectal block, oral and/or intravenous drugs such as Fentanyl or Demerol, chilled irrigant, and irrigant containing anesthesia.
- C. Vaporization will be performed with the Laserscope ADD (Angled Delivery Device) fiber, which is a 600 um bare fiber with a quartz capsule over the 70 degree lateral deflecting quartz element and a spot diameter of 1.2 mm at 2 mm.
- D. The laser fiber will be introduced through the lumen of a standard 22 Fr continuous flow laser cystoscope, and sterile water will be used as the irrigant.
- E. KTP laser energy will be generated by a
high power 532 nm laser capable of delivering 80 W of KTP laser power to tissue. - F. Lasing will be performed under direct visualization using a free beam technique, holding the fiber 1-2 mm away from the tissue and vaporizing the lateral lobes beginning at the bladder neck.
- G. The visible laser beam will be slowly moved along the length and breadth of the lateral lobe as the tissue is vaporized. The laser will be carefully directed toward the apical tissue making sure to protect the external sphincter.
- H. Both lateral lobes will be vaporized evenly to the level of the capsular fibers.
- I. The median lobe will be vaporized evenly to the level. of the transverse fibers of the vesicle neck. If the median lobe is too large, then it should be partially vaporized before ablation of the lateral lobes to facilitate the movement of the scope and irrigation, and then the remainder will be flattened out later during the procedure.
- J. The procedure should preserve the distal crista urethralis and the verumontanum.
- K. The end point of the procedure should be judged by the size and appearance of the large transurethral resection-like cavity and by the diminished efficacy of the vaporization effect at the prostatic capsule. The median and lateral hypertrophic tissue must be vaporized to the level-of the transverse fibers and any lingering loose fibers should be removed prior to completion of the treatment.
- L. Rarely will arterial bleeders be encountered, however, if an arterial bleeder is encountered, then coagulate the vessel at a distance of approximately 3 to 4 mm.
- M. The cystoscope is removed and, if necessary, a foley catheter is inserted at the physician's discretion.
- N. This is an outpatient procedure and subjects will be released from the hospital as outpatients per the discretion of the Surgeon.
-
FIGS. 8 and 9 illustrate the different optical penetration depths of the 532 nm wavelength and 1064 nm wavelength used in prior art procedures. See, S. L. Jacques. Laser-tissue interaction. Photochemical, photothermal and photomechanical. Surg. Clin N. Am. 1992; 72(3):531-558. The optical penetration depth of the 1064 wavelength beam from Nd:YAG laser beam is about 10 mm, which is 13 times larger than the penetration depth of the second harmonic 532 wavelength laser beam, which is about 0.8 mm. As a result, the 1064 laser power is spread out over a much larger tissue volume than the power of the KTP laser. In case of the 1064 laser as shown inFIG. 9 , the temperature at the tissue surface barely reaches 100° C. Therefore, only a small portion of tissue gets vaporized. But a huge volume of tissue gets coagulated (see space between 100° C. and 60° C. isotherm). The consequences are the formation of edema in a huge volume of coagulated tissue, swelling of the prostate, and the patient going into retention with catheterization times of several weeks. - The 532 laser beam, in contrast, is substantially completely absorbed within less than about 1 mm of the surface of prostatic tissue. The laser power is confined to a very small tissue volume. The high volumetric power density results in a fast heating of the tissue and efficient tissue vaporization. Volumetric power density delivered to tissue is a function of the absorbtion depth, irradiance in Watts/cm2 and spot size on the surface of the tissue. The coagulation zone is very thin because of the small optical penetration depth of the 532 wavelength, and because substantially all of the radiation is converted to vaporization rather than residual heat.
- Other wavelengths which are substantially completely absorbed within less than about 1 mm of the surface of the prostatic tissue include wavelengths less than about 650 nm, for example between about 200 nm and 650 nm.
-
FIGS. 10 and 11 illustrate a profile of a beam delivered to tissue using one representative side firing optical fiber, to show spot size as a function of distance from the side of the optical fiber.FIG. 10 is an end view, showing afiber 600, cladding 601 on the fiber, anair space 602, and atip 603 through which the beam is directed by a reflecting face on the fiber. The cross-section of the beam is represented by the crossinglines tip 603. At about 2 mm from the side of thetip 603, the width is about 1 mm. At about 3 mm distance from the side of thetip 603, the beam width is about 2.2 mm. -
FIG. 11 is a side view, with like components given the same reference numbers. The beam width in this dimension is represented bylines tip 603. At about 2 mm from the side of thetip 603, the width is about 1 mm. At about 3 mm distance from the side of thetip 603, the beam width is about 1.5 mm. - Thus, the spot size at 1 mm from the side of the tip is defined basically by an elipse having a major axis of 0.7 mm, and a minor axis of 0.35 mm. The area of the spot at 1 mm is around 0.2 mm2. At 2 mm from the side, the area of the spot is about 0.8 mm2.
- For rapid procedures, according to the present invention, the spot size should be large enough that the operator can remove tissue at a reasonable rate, and see the results of a single pass of the spot over a region of tissue. If the spot size is too small, the rate of the operation is too slow. Also, if the spot size is too big, then the procedure is difficult to control precisely. A preferred spot size is less than about 1 mm2, and more particularly between about 0.8 mm2 and about 0.05 mm2. Other apparatus may be used for delivery of the beam with the desired spot size, including embodiments without diverging beams, and embodiments with converging beams.
- The irradiance of the beam at 1 mm from the side of the tip for an 80 W average power laser as described above is about 30 kiloWatts/cm2. According to the present invention, it is desirable to provide a wavelength between about 650 and 200 nm, with a spot size on the surface of the tissue less than about 0.8 mm2, and preferably greater than about 0.05 mm2, with an irradiance greater than about 10 kiloWatts/cm2, and more preferably greater than 20 kiloWatts/cm2, and even more preferably 30 kiloWatts/cm2 or higher.
-
FIG. 12 shows, heuristically, how vaporization rate and coagulation rate depend on the volumetric power density. The vaporization rate (in mm/s) is defined as tissue depth that is vaporized per time interval. The coagulation rate (in mm/s) is defined as the depth of residual coagulated tissue that remains after a certain time of vaporization. - Below a certain volumetric power density, referred to as a “vaporization threshold” in
FIG. 12 , no tissue gets vaporized. All laser energy stays inside the tissue. Tissue coagulation occurs where the tissue temperature rises above approximately 60° C. As the volumetric power density is increased a bigger and bigger tissue volume gets coagulated. - At the vaporization threshold, vaporization starts. Above the vaporization threshold the vaporization rate can be considered to increase linearly with the volumetric power density for the purpose of understanding the present invention, and as described by a steady state model for continuous wave laser tissue ablation, known by those familiar with the art of laser-tissue interaction.
- As more and more laser energy is consumed by vaporization of the tissue, the amount of laser energy leading to residual tissue coagulation gets smaller, i.e. the amount of residual coagulation drops. Thus, extent of the zone of thermal damage characterized by tissue coagulation left after the procedure gets smaller with increasing volumetric power density, while the rate of vaporization increases. Substantial and surprising improvement in results is achieved.
- Publications about visual laser ablation of the prostate (VLAP) that is performed with an Nd:YAG laser at 1064 nm have shown that this type of laser is not able to vaporize a significant amount of tissue. Histology studies have shown that the 1064 nm laser induces deep coagulation in the tissue that results in edema and delayed tissue sloughing. This effect was described by Kuntzman, et al., High-power potassium titanylphosphate laser vaporization prostatectomy. Mayo Clin Proc 1998:73:798-801. Thus, in the heuristic diagram of
FIG. 12 , the VLAP procedure is believed to lie aroundpoint 650, barely above the vaporization threshold. Also, prior art technologies using 532 nm with spot sizes on the order of 1 mm2 with average output power of 60 Watts, are believed to lie, heuristically, aroundpoint 651 in theFIG. 12 . Kuntzman et al present results for the coagulation depth of a 60 Wcontinuous wave 532 nm laser, with suggested operation at a distance of 2 mm from the side of the tip, yielding less than 5 kiloWatts/cm2 irradiance. - As the laser power is further increased to 80 W, and the side firing probe is placed less than 1 mm from the tissue for a small spot size, the ablation rate further increases and the coagulation rate further drops, so that the procedure lies heuristically at
point 652 inFIG. 12 . - An 80 Watt KTP laser can used to easily reach irradiance levels that vaporize substantially more tissue than is left as residual coagulation after the procedure. More precisely, the vaporization rate is substantially higher than the coagulation rate as given by the definition above, using high irradiance levels that are easily achieved with higher power lasers.
- While the invention has been particularly shown and described with reference to preferred embodiments thereof, it will be understood by those skilled in the art, that various changes in form and details may be made therein without departing from the spirit and scope of the invention, as defined by the appended claims.
Claims (21)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/614,265 US20070225696A1 (en) | 2000-12-15 | 2006-12-21 | Surgical apparatus for laser ablation of soft tissue |
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/737,721 US6554824B2 (en) | 2000-12-15 | 2000-12-15 | Methods for laser treatment of soft tissue |
US33648101P | 2001-10-24 | 2001-10-24 | |
US33872801P | 2001-11-05 | 2001-11-05 | |
US33781001P | 2001-11-05 | 2001-11-05 | |
US10/278,723 US6986764B2 (en) | 2000-12-15 | 2002-10-23 | Method and system for photoselective vaporization of the prostate, and other tissue |
US11/191,197 US20060084959A1 (en) | 2000-12-15 | 2005-07-27 | Method and system for photoselective vaporization of the prostate, and other tissue |
US11/614,265 US20070225696A1 (en) | 2000-12-15 | 2006-12-21 | Surgical apparatus for laser ablation of soft tissue |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/191,197 Continuation US20060084959A1 (en) | 2000-12-15 | 2005-07-27 | Method and system for photoselective vaporization of the prostate, and other tissue |
Publications (1)
Publication Number | Publication Date |
---|---|
US20070225696A1 true US20070225696A1 (en) | 2007-09-27 |
Family
ID=33459292
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/278,723 Expired - Lifetime US6986764B2 (en) | 2000-12-15 | 2002-10-23 | Method and system for photoselective vaporization of the prostate, and other tissue |
US10/875,366 Abandoned US20050027286A1 (en) | 2000-12-15 | 2004-06-24 | Method and system for photoselective vaporization of the prostate, and other tissue |
US10/876,316 Abandoned US20040236319A1 (en) | 2000-12-15 | 2004-06-24 | Method and system for photoselective vaporization of the prostate, and other tissue |
US10/876,311 Abandoned US20040236318A1 (en) | 2000-12-15 | 2004-06-24 | Method and system for photoselective vaporization of the prostate, and other tissue |
US11/191,197 Abandoned US20060084959A1 (en) | 2000-12-15 | 2005-07-27 | Method and system for photoselective vaporization of the prostate, and other tissue |
US11/614,265 Abandoned US20070225696A1 (en) | 2000-12-15 | 2006-12-21 | Surgical apparatus for laser ablation of soft tissue |
US12/145,370 Abandoned US20080262485A1 (en) | 2000-12-15 | 2008-06-24 | Method and system for photoselective vaporization of the prostate, and other tissue |
US14/157,410 Expired - Fee Related US10653482B2 (en) | 2000-12-15 | 2014-01-16 | System for vaporization of tissue |
Family Applications Before (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/278,723 Expired - Lifetime US6986764B2 (en) | 2000-12-15 | 2002-10-23 | Method and system for photoselective vaporization of the prostate, and other tissue |
US10/875,366 Abandoned US20050027286A1 (en) | 2000-12-15 | 2004-06-24 | Method and system for photoselective vaporization of the prostate, and other tissue |
US10/876,316 Abandoned US20040236319A1 (en) | 2000-12-15 | 2004-06-24 | Method and system for photoselective vaporization of the prostate, and other tissue |
US10/876,311 Abandoned US20040236318A1 (en) | 2000-12-15 | 2004-06-24 | Method and system for photoselective vaporization of the prostate, and other tissue |
US11/191,197 Abandoned US20060084959A1 (en) | 2000-12-15 | 2005-07-27 | Method and system for photoselective vaporization of the prostate, and other tissue |
Family Applications After (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/145,370 Abandoned US20080262485A1 (en) | 2000-12-15 | 2008-06-24 | Method and system for photoselective vaporization of the prostate, and other tissue |
US14/157,410 Expired - Fee Related US10653482B2 (en) | 2000-12-15 | 2014-01-16 | System for vaporization of tissue |
Country Status (1)
Country | Link |
---|---|
US (8) | US6986764B2 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050288653A1 (en) * | 2004-06-23 | 2005-12-29 | Applied Harmonics Corporation | Apparatus and method for soft tissue ablation employing high power diode-pumped laser |
US20080086118A1 (en) * | 2006-05-17 | 2008-04-10 | Applied Harmonics Corporation | Apparatus and method for diode-pumped laser ablation of soft tissue |
WO2012095873A1 (en) | 2011-01-11 | 2012-07-19 | Quanta System S.P.A. | Laser surgery device |
US8932063B2 (en) | 2011-04-15 | 2015-01-13 | Ams Research Corporation | BPH laser ablation simulation |
KR101530650B1 (en) * | 2014-08-28 | 2015-06-22 | 인덕대학교 산학협력단 | Medical laser irradiation device |
US11389241B2 (en) | 2019-01-15 | 2022-07-19 | Boston Scientific Scimed, Inc. | Alignment method and tools |
Families Citing this family (105)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9023031B2 (en) * | 1997-08-13 | 2015-05-05 | Verathon Inc. | Noninvasive devices, methods, and systems for modifying tissues |
US20100114087A1 (en) * | 1998-02-19 | 2010-05-06 | Edwards Stuart D | Methods and devices for treating urinary incontinence |
US8256430B2 (en) | 2001-06-15 | 2012-09-04 | Monteris Medical, Inc. | Hyperthermia treatment and probe therefor |
US7306591B2 (en) | 2000-10-02 | 2007-12-11 | Novasys Medical, Inc. | Apparatus and methods for treating female urinary incontinence |
US6986764B2 (en) * | 2000-12-15 | 2006-01-17 | Laserscope | Method and system for photoselective vaporization of the prostate, and other tissue |
EP1617776B1 (en) * | 2003-05-01 | 2015-09-02 | Covidien AG | System for programing and controlling an electrosurgical generator system |
US7313155B1 (en) * | 2004-02-12 | 2007-12-25 | Liyue Mu | High power Q-switched laser for soft tissue ablation |
DE602005019367D1 (en) * | 2004-12-15 | 2010-04-01 | Dornier Medtech Systems Gmbh | Enhanced cell therapy and tissue regeneration via shock waves in patients with cardiovascular and neurological diseases |
JP2008523881A (en) * | 2004-12-20 | 2008-07-10 | コーニンクレッカ フィリップス エレクトロニクス エヌ ヴィ | Apparatus and method for investigating body structure |
ES2668959T3 (en) | 2005-03-31 | 2018-05-23 | Esther Mayer | Probe device for tissue photobiomodulation that covers a body cavity |
US20060234959A1 (en) * | 2005-04-14 | 2006-10-19 | Advanced Photodynamic Technologies, Inc. | Photodynamic therapy utilizing multiple duty cycle light modulation |
US7909817B2 (en) | 2005-06-08 | 2011-03-22 | Innovaquartz, Inc. (AMS Research Corporation) | Lateral laser fiber for high average power and peak pulse energy |
US7862556B2 (en) | 2005-06-17 | 2011-01-04 | Applied Harmonics Corporation | Surgical system that ablates soft tissue |
US7655003B2 (en) | 2005-06-22 | 2010-02-02 | Smith & Nephew, Inc. | Electrosurgical power control |
DE102005036410A1 (en) * | 2005-07-29 | 2007-02-01 | Biocam Gmbh | Method for determining the oxygen partial pressure distribution in at least one tissue surface section, in particular skin tissue surface section |
DE102005037043C5 (en) * | 2005-08-05 | 2017-12-14 | Dornier Medtech Systems Gmbh | Shock wave therapy device with image acquisition |
US20070050001A1 (en) * | 2005-08-26 | 2007-03-01 | Solarant Medical, Inc. | Adjustable open loop control devices and methods |
US7556414B2 (en) * | 2005-10-07 | 2009-07-07 | Karl Storz Endovision, Inc. | Endoscopic light source safety and control system with optical sensor |
US7519253B2 (en) | 2005-11-18 | 2009-04-14 | Omni Sciences, Inc. | Broadband or mid-infrared fiber light sources |
US20070129712A1 (en) * | 2005-12-01 | 2007-06-07 | Ceramoptec Industries, Inc. | Benign prostate hyperplasia treatment using photosensitizer and laser ablation |
WO2007092805A2 (en) * | 2006-02-07 | 2007-08-16 | Ams Research Corporation | Laparoscopic laser device and method |
US20070270647A1 (en) * | 2006-05-19 | 2007-11-22 | Ams Research Corporation | Handle for Multifunction Endoscope |
US20080039828A1 (en) * | 2006-08-10 | 2008-02-14 | Jimenez Jose W | Laser Tissue Vaporization |
WO2008073263A1 (en) * | 2006-12-07 | 2008-06-19 | Ams Research Corporation | Side fire optical device for laterally redirecting high power electromagnetic energy |
US20080154344A1 (en) * | 2006-12-22 | 2008-06-26 | Trusty Robert M | System and method for treating benign prostatic hyperplasia |
US9232959B2 (en) | 2007-01-02 | 2016-01-12 | Aquabeam, Llc | Multi fluid tissue resection methods and devices |
EP2267403A3 (en) * | 2007-02-21 | 2011-04-20 | Agfa HealthCare N.V. | System and method for optical coherence tomography |
ATE474205T1 (en) * | 2007-02-21 | 2010-07-15 | Agfa Healthcare Nv | SYSTEM AND METHOD FOR OPTICAL COHERENCE TOMOGRAPHY |
EP2339329A3 (en) * | 2007-02-21 | 2012-04-04 | Agfa HealthCare N.V. | System and method for optical coherence tomography |
EP1962051A1 (en) * | 2007-02-21 | 2008-08-27 | Agfa HealthCare N.V. | System and method for optical coherence tomography |
EP1962049B1 (en) * | 2007-02-21 | 2015-12-23 | Agfa HealthCare N.V. | System and method for optical coherence tomography |
EP2365316B1 (en) * | 2007-02-21 | 2014-10-22 | Agfa HealthCare N.V. | System for optical coherence tomography |
US8202268B1 (en) * | 2007-03-18 | 2012-06-19 | Lockheed Martin Corporation | Method and multiple-mode device for high-power short-pulse laser ablation and CW cauterization of bodily tissues |
WO2008144641A1 (en) * | 2007-05-17 | 2008-11-27 | Ceramoptec Industries, Inc. | Device and method for benign prostatic hyperplasia laser treatment |
US20080287936A1 (en) * | 2007-05-18 | 2008-11-20 | Stinson Douglas G | Telescope with Integrated Optical Filter |
DE202007008378U1 (en) * | 2007-06-15 | 2007-08-23 | Ceramoptec Gmbh | Urological diode laser systems with glass fiber application system |
US9861424B2 (en) | 2007-07-11 | 2018-01-09 | Covidien Lp | Measurement and control systems and methods for electrosurgical procedures |
US8152800B2 (en) | 2007-07-30 | 2012-04-10 | Vivant Medical, Inc. | Electrosurgical systems and printed circuit boards for use therewith |
US8858542B2 (en) | 2007-08-03 | 2014-10-14 | Ams Research Corporation | Side-firing fiber delivery device with active cooling cap |
US7645142B2 (en) * | 2007-09-05 | 2010-01-12 | Vivant Medical, Inc. | Electrical receptacle assembly |
US8747398B2 (en) | 2007-09-13 | 2014-06-10 | Covidien Lp | Frequency tuning in a microwave electrosurgical system |
WO2009088550A2 (en) * | 2007-10-19 | 2009-07-16 | Lockheed Martin Corporation | System and method for conditioning animal tissue using laser light |
CN102014780B (en) * | 2008-03-04 | 2014-04-16 | 科威中公司 | Contact laser ablation of tissue |
EP2259742B1 (en) | 2008-03-06 | 2020-01-01 | AquaBeam LLC | Tissue ablation and cautery with optical energy carried in fluid stream |
US8603123B2 (en) * | 2008-04-28 | 2013-12-10 | Urotech, Inc. | Benign prostatic hyperplasia surgical system featuring mechanical coring probe with live aspiration |
US20090326525A1 (en) * | 2008-06-26 | 2009-12-31 | Jessica Hixon | Laser fiber capillary apparatus and method |
WO2010014224A2 (en) * | 2008-07-28 | 2010-02-04 | Xintec Corporation | Multi-wavelength laser and method for contact ablation of tissue |
WO2010014787A1 (en) * | 2008-07-30 | 2010-02-04 | Ams Research Corporation | Optical device having fluorocarbon polymer layer |
US20100030202A1 (en) | 2008-08-01 | 2010-02-04 | Markus Rheinwald | Methods and Devices for the Treatment of BPH and for Ablation of Tissue |
US8728092B2 (en) * | 2008-08-14 | 2014-05-20 | Monteris Medical Corporation | Stereotactic drive system |
US8747418B2 (en) * | 2008-08-15 | 2014-06-10 | Monteris Medical Corporation | Trajectory guide |
EP2358436B1 (en) * | 2008-09-16 | 2015-08-05 | EL.EN. S.p.A. | Device for regenerative therapy by high intensity laser therapy |
US20100087808A1 (en) * | 2008-10-03 | 2010-04-08 | Vivant Medical, Inc. | Combined Frequency Microwave Ablation System, Devices and Methods of Use |
US8899844B2 (en) * | 2008-12-01 | 2014-12-02 | Ams Research Corporation | Optical device |
US8428095B2 (en) | 2008-12-22 | 2013-04-23 | Ams Research Corporation | Laser resonator |
US9848904B2 (en) | 2009-03-06 | 2017-12-26 | Procept Biorobotics Corporation | Tissue resection and treatment with shedding pulses |
AU2010229776B2 (en) * | 2009-03-27 | 2013-08-01 | Ams Research Corporation | Laser modulation for coagulation |
WO2011008646A1 (en) | 2009-07-14 | 2011-01-20 | Brian Cisel | Laser surgery device and method |
DE102009033671B3 (en) * | 2009-07-17 | 2010-09-02 | Erbe Elektromedizin Gmbh | Vaporization device for vaporizing biological tissues, has vaporization probe with gas outlet nozzle at distal end for discharging combustible gas mixture, where supply line is provided for supplying combustible gas mixture |
US8979871B2 (en) | 2009-08-13 | 2015-03-17 | Monteris Medical Corporation | Image-guided therapy of a tissue |
US9106038B2 (en) | 2009-10-15 | 2015-08-11 | Masimo Corporation | Pulse oximetry system with low noise cable hub |
US8430871B2 (en) | 2009-10-28 | 2013-04-30 | Covidien Lp | System and method for monitoring ablation size |
CA2781215A1 (en) | 2009-11-18 | 2011-05-26 | Boston Scientific Scimed, Inc. | Methods and apparatus related to a side-fire member having a doped silica component |
EP2502104B1 (en) * | 2009-11-18 | 2020-09-02 | Boston Scientific Scimed, Inc. | Apparatus related to a distal end of a side-fire optical fiber having multiple capillary components |
GB2487882B (en) | 2009-12-04 | 2017-03-29 | Masimo Corp | Calibration for multi-stage physiological monitors |
WO2011084863A2 (en) | 2010-01-07 | 2011-07-14 | Cheetah Omni, Llc | Fiber lasers and mid-infrared light sources in methods and systems for selective biological tissue processing and spectroscopy |
US20120143176A1 (en) * | 2010-03-18 | 2012-06-07 | Metalase, Inc. | Laser systems and methods for vaporization of prostate and other tissue |
WO2011133941A2 (en) | 2010-04-22 | 2011-10-27 | Precise Light Surgical, Inc. | Flash vaporization surgical systems |
US8936592B2 (en) | 2010-06-03 | 2015-01-20 | Ams Research Corporation | Laser tissue ablation system |
US8685011B2 (en) | 2010-12-15 | 2014-04-01 | Ams Research Corporation | Tunica ablation |
US8672929B2 (en) | 2010-12-15 | 2014-03-18 | Ams Research Corporation | Laser probe tip |
US8876804B2 (en) | 2010-12-17 | 2014-11-04 | Ams Research Corporation | Ablation device |
BR112013021463A2 (en) | 2011-02-24 | 2016-11-01 | Eximo Medical Ltd | tissue resection hybrid catheter |
US9220887B2 (en) | 2011-06-09 | 2015-12-29 | Astora Women's Health LLC | Electrode lead including a deployable tissue anchor |
US10357661B2 (en) * | 2011-09-30 | 2019-07-23 | Percuvision, Llc | Medical device and method for internal healing and antimicrobial purposes |
CN108606773B (en) | 2012-02-29 | 2020-08-11 | 普罗赛普特生物机器人公司 | Automated image-guided tissue ablation and treatment |
WO2014011898A1 (en) * | 2012-07-11 | 2014-01-16 | Anderson David J | Managed fiber connectivity systems |
JP6403695B2 (en) | 2013-02-14 | 2018-10-10 | プロセプト バイオロボティクス コーポレイション | Aqua ablation aqua beam ophthalmic surgery method and apparatus |
JP6461971B2 (en) | 2013-09-06 | 2019-01-30 | プロセプト バイオロボティクス コーポレイション | Tissue excision and treatment using scattered pulses |
US20150224249A1 (en) * | 2014-02-12 | 2015-08-13 | Boston Scientific Scimed, Inc. | Tissue enucleation devices and related methods |
US10675113B2 (en) | 2014-03-18 | 2020-06-09 | Monteris Medical Corporation | Automated therapy of a three-dimensional tissue region |
US9700342B2 (en) | 2014-03-18 | 2017-07-11 | Monteris Medical Corporation | Image-guided therapy of a tissue |
WO2015143025A1 (en) | 2014-03-18 | 2015-09-24 | Monteris Medical Corporation | Image-guided therapy of a tissue |
EP3552571B1 (en) | 2014-05-18 | 2024-09-25 | Eximo Medical Ltd. | System for tissue ablation using pulsed laser |
BR112016031037B1 (en) | 2014-06-30 | 2023-02-07 | Procept Biorobotics Corporation | DEVICE FOR ABLATING VASCULAR TISSUE |
CN107072591B (en) | 2014-09-05 | 2021-10-26 | 普罗赛普特生物机器人公司 | Physician-controlled tissue ablation in conjunction with treatment mapping of target organ images |
US9956040B1 (en) * | 2014-09-30 | 2018-05-01 | Emilio F. Lastarria | Laser surgery system with safety control of non-target tissue temperature and method of use |
US9323005B1 (en) | 2014-12-22 | 2016-04-26 | InnovaQuartz LLC | Redirecting electromagnetic radiation |
US9488782B2 (en) | 2014-12-22 | 2016-11-08 | InnovaQuartz LLC | Redirecting electromagnetic radiation |
US9220563B1 (en) | 2014-12-29 | 2015-12-29 | InnovaQuartz LLC | Multiwavelength surgical laser |
US10327830B2 (en) | 2015-04-01 | 2019-06-25 | Monteris Medical Corporation | Cryotherapy, thermal therapy, temperature modulation therapy, and probe apparatus therefor |
US11826097B2 (en) | 2015-11-18 | 2023-11-28 | Cyclone Biosciences, Llc | Forming radial emissions from optical fibers |
US10092356B2 (en) | 2015-11-18 | 2018-10-09 | InnovaQuartz LLC | Radial emissions from optical fibers |
US10254534B2 (en) * | 2015-11-30 | 2019-04-09 | The Regents Of The University Of Colorado, A Body Corporate | Single multimode fiber endoscope |
US9618700B1 (en) | 2015-12-03 | 2017-04-11 | InnovaQuartz LLC | Orthogonal output optical fiber |
US9662173B1 (en) | 2015-12-24 | 2017-05-30 | Cyclone Biosciences LLC | Lateral delivery device with active cooling |
EP3995277A1 (en) * | 2016-01-29 | 2022-05-11 | Seurat Technologies, Inc. | System for additive manufacturing |
WO2017191644A1 (en) | 2016-05-05 | 2017-11-09 | Eximo Medical Ltd | Apparatus and methods for resecting and/or ablating an undesired tissue |
EP3512448B1 (en) * | 2016-09-16 | 2021-03-31 | Boston Scientific Scimed, Inc. | Dual-wavelength laser treatment |
AU2017339894B2 (en) * | 2016-10-04 | 2022-12-15 | Boston Scientific Scimed, Inc. | Tailored laser pulses for surgical applications |
EP3600110A4 (en) | 2017-03-20 | 2020-09-16 | Precise Light Surgical, Inc. | Soft tissue selective ablation surgical systems |
US11622808B2 (en) * | 2019-08-05 | 2023-04-11 | Gyrus Acmi, Inc. | Endoscopic laser energy delivery system and methods of use |
US11672598B2 (en) | 2019-09-24 | 2023-06-13 | Boston Scientific Limited | Medical systems, devices, and related methods |
US12036418B2 (en) * | 2019-12-31 | 2024-07-16 | Gyrus Acmi, Inc. | Surgical devices for treating body tissue and diagnosing patients |
US12038322B2 (en) | 2022-06-21 | 2024-07-16 | Eximo Medical Ltd. | Devices and methods for testing ablation systems |
Citations (74)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4383318A (en) * | 1980-12-15 | 1983-05-10 | Hughes Aircraft Company | Laser pumping system |
US4402569A (en) * | 1980-05-31 | 1983-09-06 | Barr & Stroud Limited | Optical fibre light guides for use with lasers |
US4418689A (en) * | 1980-09-22 | 1983-12-06 | Olympus Optical Co., Ltd. | Laser device for an endoscope |
US4646737A (en) * | 1983-06-13 | 1987-03-03 | Laserscope, Inc. | Localized heat applying medical device |
US4722337A (en) * | 1983-08-22 | 1988-02-02 | Laserscope | Medical laser peripherals and connector system |
US4760840A (en) * | 1986-12-16 | 1988-08-02 | The Regents Of The University Of California | Endoscopic laser instrument |
US4802461A (en) * | 1987-08-26 | 1989-02-07 | Candela Laser Corporation | Rigid endoscope with flexible tip |
US4834091A (en) * | 1987-04-10 | 1989-05-30 | Ott Douglas E | Intrauterine fallopian tube ostial plug and surgical process |
US4836189A (en) * | 1988-07-27 | 1989-06-06 | Welch Allyn, Inc. | Video hysteroscope |
US4907235A (en) * | 1988-04-01 | 1990-03-06 | Laserscope | Intra-cavity beam relay for optical harmonic generation |
US4944738A (en) * | 1987-10-13 | 1990-07-31 | Rodriguez Michael A | Surgical laser backstop instrument |
US4981138A (en) * | 1988-06-30 | 1991-01-01 | Yale University | Endoscopic fiberoptic fluorescence spectrometer |
US5025446A (en) * | 1988-04-01 | 1991-06-18 | Laserscope | Intra-cavity beam relay for optical harmonic generation |
US5147353A (en) * | 1990-03-23 | 1992-09-15 | Myriadlase, Inc. | Medical method for applying high energy light and heat for gynecological sterilization procedures |
US5151909A (en) * | 1990-10-16 | 1992-09-29 | Laserscope | Frequency doubled solid state laser having programmable pump power modes and method for controllable lasers |
US5231641A (en) * | 1992-01-21 | 1993-07-27 | Laserscope | Crystalline slab laser with intracavity non-linear optic |
US5242390A (en) * | 1991-05-03 | 1993-09-07 | Goldrath Milton H | Endometrium coagulating surgical method for thermal destruction of the endometrium |
US5243615A (en) * | 1991-11-20 | 1993-09-07 | Laserscope | High-powered intracavity non-linear optic laser |
US5242437A (en) * | 1988-06-10 | 1993-09-07 | Trimedyne Laser Systems, Inc. | Medical device applying localized high intensity light and heat, particularly for destruction of the endometrium |
US5249192A (en) * | 1991-06-27 | 1993-09-28 | Laserscope | Multiple frequency medical laser |
US5257991A (en) * | 1990-11-15 | 1993-11-02 | Laserscope | Instrumentation for directing light at an angle |
US5258989A (en) * | 1990-02-12 | 1993-11-02 | Diomed Limited | Solid state laser diode light source |
US5269779A (en) * | 1988-06-06 | 1993-12-14 | Sumitomo Electric Industries, Ltd. | Laser beam guiding fiber assembly |
US5292320A (en) * | 1992-07-06 | 1994-03-08 | Ceramoptec, Inc. | Radial medical laser delivery device |
US5300061A (en) * | 1991-08-29 | 1994-04-05 | Surgical Technologies, Inc. | Laser delivery probe having a mechanically free floating sheath |
US5312392A (en) * | 1992-08-31 | 1994-05-17 | Messerschmitt-Boelkow-Blohm Ag | Interstitial laser coagulation treatment for benign prostatic hyperplasia |
US5312396A (en) * | 1990-09-06 | 1994-05-17 | Massachusetts Institute Of Technology | Pulsed laser system for the surgical removal of tissue |
US5409483A (en) * | 1993-01-22 | 1995-04-25 | Jeffrey H. Reese | Direct visualization surgical probe |
US5409481A (en) * | 1992-05-21 | 1995-04-25 | Laserscope | Laser tissue welding control system |
US5421323A (en) * | 1992-12-02 | 1995-06-06 | Richard Wolf Gmbh | Endoscope with additional viewing aperture |
US5428699A (en) * | 1993-07-02 | 1995-06-27 | Laserscope | Probe having optical fiber for laterally directing laser beam |
US5437660A (en) * | 1991-12-30 | 1995-08-01 | Trimedyne, Inc. | Tissue ablation and a lateral-lasing fiber optic device therefor |
US5449354A (en) * | 1992-12-15 | 1995-09-12 | Laser Industries Ltd | Device for treating the interior of body cavities with laser energy |
US5451221A (en) * | 1993-12-27 | 1995-09-19 | Cynosure, Inc. | Endoscopic light delivery system |
US5486171A (en) * | 1993-02-08 | 1996-01-23 | Xintec Corporation | Transparent cap fiber optica laser beam angle delivery device |
US5495541A (en) * | 1994-04-19 | 1996-02-27 | Murray; Steven C. | Optical delivery device with high numerical aperture curved waveguide |
US5509917A (en) * | 1994-06-28 | 1996-04-23 | Ceramoptec Industries, Inc. | Lensed caps for radial medical laser delivery devices |
US5520679A (en) * | 1992-12-03 | 1996-05-28 | Lasersight, Inc. | Ophthalmic surgery method using non-contact scanning laser |
US5542944A (en) * | 1993-04-19 | 1996-08-06 | Bhatta; Krishan M. | Surgical device and method |
US5607420A (en) * | 1992-02-25 | 1997-03-04 | Surgical Laser Technologies, Inc. | Surgical tool for use with a contact laser |
US5628744A (en) * | 1993-12-21 | 1997-05-13 | Laserscope | Treatment beam handpiece |
US5632739A (en) * | 1994-10-13 | 1997-05-27 | The General Hospital Corporation | Two-pulse, lateral tissue illuminator |
US5658323A (en) * | 1995-07-12 | 1997-08-19 | Miller; Iain D. | Method and apparatus for dermatology treatment |
US5662646A (en) * | 1992-11-04 | 1997-09-02 | Fumich; Robert Mark | Method and apparatus for laser surgery |
US5668903A (en) * | 1994-12-22 | 1997-09-16 | Ceramoptec Industries, Inc. | Compound laser system for high power densities |
US5733279A (en) * | 1994-12-21 | 1998-03-31 | Laser Industries, Ltd. | Device for treating the interior of body cavities with laser energy |
US5746760A (en) * | 1995-01-17 | 1998-05-05 | Laserscope | Semi-automatic tissue morcellation device |
US5757827A (en) * | 1994-07-26 | 1998-05-26 | Hitachi Metals, Ltd. | Second harmonic generating apparatus and apparatus employing laser |
US5772658A (en) * | 1994-12-20 | 1998-06-30 | Laser Industries, Ltd. | Side-emitting optical fibers for lasers |
US5778395A (en) * | 1995-10-23 | 1998-07-07 | Stac, Inc. | System for backing up files from disk volumes on multiple nodes of a computer network |
US5776175A (en) * | 1995-09-29 | 1998-07-07 | Esc Medical Systems Ltd. | Method and apparatus for treatment of cancer using pulsed electromagnetic radiation |
US5798518A (en) * | 1995-07-28 | 1998-08-25 | Laserscope | Medical laser calibration system and method |
US5807389A (en) * | 1991-08-16 | 1998-09-15 | Myriadlase, Inc. | Laterally reflecting tip for laser transmitting fiber |
US5841800A (en) * | 1995-07-28 | 1998-11-24 | Laserscope | Desktop medical laser generator |
US5843026A (en) * | 1992-08-12 | 1998-12-01 | Vidamed, Inc. | BPH ablation method and apparatus |
US5879376A (en) * | 1995-07-12 | 1999-03-09 | Luxar Corporation | Method and apparatus for dermatology treatment |
US5895356A (en) * | 1995-11-15 | 1999-04-20 | American Medical Systems, Inc. | Apparatus and method for transurethral focussed ultrasound therapy |
US6011890A (en) * | 1997-08-06 | 2000-01-04 | Ceram Optec Industries, Inc. | High power, multi-diode laser system |
US6024751A (en) * | 1997-04-11 | 2000-02-15 | Coherent Inc. | Method and apparatus for transurethral resection of the prostate |
US6064914A (en) * | 1998-04-01 | 2000-05-16 | Trachtenberg; John R. | Thermotherapy method |
US6086580A (en) * | 1996-12-05 | 2000-07-11 | Centre International De Recherches Dermatologiques | Laser treatment/ablation of skin tissue |
US6164280A (en) * | 1990-03-23 | 2000-12-26 | Myriadlase, Inc. | Applying high energy light and heat for gynecological sterilization procedures |
US6379347B1 (en) * | 1998-05-28 | 2002-04-30 | Terumo Kabushiki Kaisha | Energy irradiation apparatus |
US6389313B1 (en) * | 1999-03-26 | 2002-05-14 | Kevin S. Marchitto | Laser probes for drug permeation |
US6423055B1 (en) * | 1999-07-14 | 2002-07-23 | Cardiofocus, Inc. | Phototherapeutic wave guide apparatus |
US6482199B1 (en) * | 1997-06-04 | 2002-11-19 | Joseph Neev | Method and apparatus for high precision variable rate material, removal and modification |
US20020193850A1 (en) * | 1993-09-29 | 2002-12-19 | Selman Steven H. | Use of photodynamic therapy to treat prostatic tissue |
US6530921B1 (en) * | 1999-07-30 | 2003-03-11 | Terumo Kabushiki Kaisha | Laser irradiation apparatus |
US6554825B1 (en) * | 2000-05-09 | 2003-04-29 | Laserscope | Variable pulse duration, adjustable wavelength medical laser system |
US6554824B2 (en) * | 2000-12-15 | 2003-04-29 | Laserscope | Methods for laser treatment of soft tissue |
US6596017B1 (en) * | 1998-09-10 | 2003-07-22 | Prostalund Operations Ab | Device for heat treatment of body tissue |
US6699239B1 (en) * | 1998-05-18 | 2004-03-02 | Dornier Medtech Systems Gmbh | Laser instrument |
US6814712B1 (en) * | 1992-08-12 | 2004-11-09 | Vidamed, Inc. | Medical probe device and method |
US20050288653A1 (en) * | 2004-06-23 | 2005-12-29 | Applied Harmonics Corporation | Apparatus and method for soft tissue ablation employing high power diode-pumped laser |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4784135A (en) * | 1982-12-09 | 1988-11-15 | International Business Machines Corporation | Far ultraviolet surgical and dental procedures |
US4648892A (en) * | 1985-03-22 | 1987-03-10 | Massachusetts Institute Of Technology | Method for making optical shield for a laser catheter |
US5071422A (en) * | 1985-04-24 | 1991-12-10 | Candela Laser Corporation | Use of lasers to break down objects |
US4862886A (en) * | 1985-05-08 | 1989-09-05 | Summit Technology Inc. | Laser angioplasty |
US5066291A (en) * | 1990-04-25 | 1991-11-19 | Cincinnati Sub-Zero Products, Inc. | Solid-state laser frequency conversion system |
GB9211085D0 (en) * | 1992-05-23 | 1992-07-08 | Tippey Keith E | Electrical stimulation |
US5322507A (en) * | 1992-08-11 | 1994-06-21 | Myriadlase, Inc. | Endoscope for treatment of prostate |
FR2704151B1 (en) * | 1993-04-21 | 1995-07-13 | Klotz Antoine Olivier | Electronic device intended for the adrenergic stimulation of the sympathetic system relating to the venous media. |
US5487740A (en) * | 1994-03-02 | 1996-01-30 | Energy Life Systems Corporation | Laser device for ablation of human tissue |
US5476461A (en) * | 1994-05-13 | 1995-12-19 | Cynosure, Inc. | Endoscopic light delivery system |
US6016324A (en) * | 1994-08-24 | 2000-01-18 | Jmar Research, Inc. | Short pulse laser system |
US5599349A (en) * | 1994-09-30 | 1997-02-04 | Circon Corporation | V shaped grooved roller electrode for a resectoscope |
US6197025B1 (en) * | 1994-09-30 | 2001-03-06 | Circon Corporation | Grooved slider electrode for a resectoscope |
DE69628709T2 (en) * | 1995-09-20 | 2004-04-29 | Mitsubishi Materials Corp. | Frequency converter and frequency conversion method with lithium tetraborate, and optical device with this frequency converter |
GB9521784D0 (en) | 1995-10-24 | 1996-01-03 | Rosslyn Medical Ltd | Diagnostic apparatus |
US6033400A (en) * | 1996-04-19 | 2000-03-07 | Circon Corporation | Shaped electrode for a resectoscope |
US5742718A (en) * | 1996-08-13 | 1998-04-21 | Eclipse Surgical Technologies, Inc. | Proprietary fiber connector and electronic security system |
DE19703208C2 (en) | 1997-01-29 | 1999-03-04 | Baasel Carl Lasertech | Device for laser ablation of tissue |
AUPO799197A0 (en) * | 1997-07-15 | 1997-08-07 | Silverbrook Research Pty Ltd | Image processing method and apparatus (ART01) |
US6055458A (en) * | 1997-08-28 | 2000-04-25 | Bausch & Lomb Surgical, Inc. | Modes/surgical functions |
US6110195A (en) * | 1998-06-01 | 2000-08-29 | Altralight, Inc. | Method and apparatus for surgical and dermatological treatment by multi-wavelength laser light |
US6149643A (en) * | 1998-09-04 | 2000-11-21 | Sunrise Technologies International, Inc. | Method and apparatus for exposing a human eye to a controlled pattern of radiation |
US6112747A (en) * | 1998-11-06 | 2000-09-05 | Jones; Jesse M. | Method of sterilizing females |
SE522249C2 (en) * | 1999-01-13 | 2004-01-27 | Biolight Patent Holding Ab | Control device for controlling external processing by light |
US6200265B1 (en) * | 1999-04-16 | 2001-03-13 | Medtronic, Inc. | Peripheral memory patch and access method for use with an implantable medical device |
US6536431B1 (en) * | 1999-04-26 | 2003-03-25 | Oxygen Leisure Products Limited | Oxygen dispenser |
US6298255B1 (en) * | 1999-06-09 | 2001-10-02 | Aspect Medical Systems, Inc. | Smart electrophysiological sensor system with automatic authentication and validation and an interface for a smart electrophysiological sensor system |
US6986764B2 (en) * | 2000-12-15 | 2006-01-17 | Laserscope | Method and system for photoselective vaporization of the prostate, and other tissue |
US6563080B2 (en) * | 2001-02-15 | 2003-05-13 | Scimed Life Systems, Inc. | Laser cutting of stents and other medical devices |
US6972268B2 (en) * | 2001-03-29 | 2005-12-06 | Gsi Lumonics Corporation | Methods and systems for processing a device, methods and systems for modeling same and the device |
US6701044B2 (en) * | 2001-08-10 | 2004-03-02 | Lightwave Electronics | Solid state laser generating UV radiation for writing fiber bragg gratings |
US6646737B2 (en) * | 2001-09-24 | 2003-11-11 | Kla-Tencor Technologies | Submicron dimensional calibration standards and methods of manufacture and use |
-
2002
- 2002-10-23 US US10/278,723 patent/US6986764B2/en not_active Expired - Lifetime
-
2004
- 2004-06-24 US US10/875,366 patent/US20050027286A1/en not_active Abandoned
- 2004-06-24 US US10/876,316 patent/US20040236319A1/en not_active Abandoned
- 2004-06-24 US US10/876,311 patent/US20040236318A1/en not_active Abandoned
-
2005
- 2005-07-27 US US11/191,197 patent/US20060084959A1/en not_active Abandoned
-
2006
- 2006-12-21 US US11/614,265 patent/US20070225696A1/en not_active Abandoned
-
2008
- 2008-06-24 US US12/145,370 patent/US20080262485A1/en not_active Abandoned
-
2014
- 2014-01-16 US US14/157,410 patent/US10653482B2/en not_active Expired - Fee Related
Patent Citations (78)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4402569A (en) * | 1980-05-31 | 1983-09-06 | Barr & Stroud Limited | Optical fibre light guides for use with lasers |
US4418689A (en) * | 1980-09-22 | 1983-12-06 | Olympus Optical Co., Ltd. | Laser device for an endoscope |
US4383318A (en) * | 1980-12-15 | 1983-05-10 | Hughes Aircraft Company | Laser pumping system |
US4646737A (en) * | 1983-06-13 | 1987-03-03 | Laserscope, Inc. | Localized heat applying medical device |
US4722337A (en) * | 1983-08-22 | 1988-02-02 | Laserscope | Medical laser peripherals and connector system |
US4760840A (en) * | 1986-12-16 | 1988-08-02 | The Regents Of The University Of California | Endoscopic laser instrument |
US4834091A (en) * | 1987-04-10 | 1989-05-30 | Ott Douglas E | Intrauterine fallopian tube ostial plug and surgical process |
US4802461A (en) * | 1987-08-26 | 1989-02-07 | Candela Laser Corporation | Rigid endoscope with flexible tip |
US4944738A (en) * | 1987-10-13 | 1990-07-31 | Rodriguez Michael A | Surgical laser backstop instrument |
US5025446A (en) * | 1988-04-01 | 1991-06-18 | Laserscope | Intra-cavity beam relay for optical harmonic generation |
US4907235A (en) * | 1988-04-01 | 1990-03-06 | Laserscope | Intra-cavity beam relay for optical harmonic generation |
US5269779A (en) * | 1988-06-06 | 1993-12-14 | Sumitomo Electric Industries, Ltd. | Laser beam guiding fiber assembly |
US5242437A (en) * | 1988-06-10 | 1993-09-07 | Trimedyne Laser Systems, Inc. | Medical device applying localized high intensity light and heat, particularly for destruction of the endometrium |
US5380317A (en) * | 1988-06-10 | 1995-01-10 | Trimedyne Laser Systems, Inc. | Medical device applying localized high intensity light and heat, particularly for destruction of the endometrium |
US5649924A (en) * | 1988-06-10 | 1997-07-22 | Trimedyne, Inc. | Medical device for irradiation of tissue |
US4981138A (en) * | 1988-06-30 | 1991-01-01 | Yale University | Endoscopic fiberoptic fluorescence spectrometer |
US4836189A (en) * | 1988-07-27 | 1989-06-06 | Welch Allyn, Inc. | Video hysteroscope |
US5258989A (en) * | 1990-02-12 | 1993-11-02 | Diomed Limited | Solid state laser diode light source |
US5147353A (en) * | 1990-03-23 | 1992-09-15 | Myriadlase, Inc. | Medical method for applying high energy light and heat for gynecological sterilization procedures |
US6164280A (en) * | 1990-03-23 | 2000-12-26 | Myriadlase, Inc. | Applying high energy light and heat for gynecological sterilization procedures |
US5312396A (en) * | 1990-09-06 | 1994-05-17 | Massachusetts Institute Of Technology | Pulsed laser system for the surgical removal of tissue |
US5151909A (en) * | 1990-10-16 | 1992-09-29 | Laserscope | Frequency doubled solid state laser having programmable pump power modes and method for controllable lasers |
US5257991A (en) * | 1990-11-15 | 1993-11-02 | Laserscope | Instrumentation for directing light at an angle |
US5242390A (en) * | 1991-05-03 | 1993-09-07 | Goldrath Milton H | Endometrium coagulating surgical method for thermal destruction of the endometrium |
US5249192A (en) * | 1991-06-27 | 1993-09-28 | Laserscope | Multiple frequency medical laser |
US5807389A (en) * | 1991-08-16 | 1998-09-15 | Myriadlase, Inc. | Laterally reflecting tip for laser transmitting fiber |
US5300061A (en) * | 1991-08-29 | 1994-04-05 | Surgical Technologies, Inc. | Laser delivery probe having a mechanically free floating sheath |
US5243615A (en) * | 1991-11-20 | 1993-09-07 | Laserscope | High-powered intracavity non-linear optic laser |
US5437660A (en) * | 1991-12-30 | 1995-08-01 | Trimedyne, Inc. | Tissue ablation and a lateral-lasing fiber optic device therefor |
US5231641A (en) * | 1992-01-21 | 1993-07-27 | Laserscope | Crystalline slab laser with intracavity non-linear optic |
US5607420A (en) * | 1992-02-25 | 1997-03-04 | Surgical Laser Technologies, Inc. | Surgical tool for use with a contact laser |
US5409481A (en) * | 1992-05-21 | 1995-04-25 | Laserscope | Laser tissue welding control system |
US5292320A (en) * | 1992-07-06 | 1994-03-08 | Ceramoptec, Inc. | Radial medical laser delivery device |
US6814712B1 (en) * | 1992-08-12 | 2004-11-09 | Vidamed, Inc. | Medical probe device and method |
US5843026A (en) * | 1992-08-12 | 1998-12-01 | Vidamed, Inc. | BPH ablation method and apparatus |
US5312392A (en) * | 1992-08-31 | 1994-05-17 | Messerschmitt-Boelkow-Blohm Ag | Interstitial laser coagulation treatment for benign prostatic hyperplasia |
US5662646A (en) * | 1992-11-04 | 1997-09-02 | Fumich; Robert Mark | Method and apparatus for laser surgery |
US5421323A (en) * | 1992-12-02 | 1995-06-06 | Richard Wolf Gmbh | Endoscope with additional viewing aperture |
US5520679A (en) * | 1992-12-03 | 1996-05-28 | Lasersight, Inc. | Ophthalmic surgery method using non-contact scanning laser |
US5449354A (en) * | 1992-12-15 | 1995-09-12 | Laser Industries Ltd | Device for treating the interior of body cavities with laser energy |
US5409483A (en) * | 1993-01-22 | 1995-04-25 | Jeffrey H. Reese | Direct visualization surgical probe |
US5486171A (en) * | 1993-02-08 | 1996-01-23 | Xintec Corporation | Transparent cap fiber optica laser beam angle delivery device |
US5542944A (en) * | 1993-04-19 | 1996-08-06 | Bhatta; Krishan M. | Surgical device and method |
US5428699A (en) * | 1993-07-02 | 1995-06-27 | Laserscope | Probe having optical fiber for laterally directing laser beam |
US20020193850A1 (en) * | 1993-09-29 | 2002-12-19 | Selman Steven H. | Use of photodynamic therapy to treat prostatic tissue |
US5628744A (en) * | 1993-12-21 | 1997-05-13 | Laserscope | Treatment beam handpiece |
US5451221A (en) * | 1993-12-27 | 1995-09-19 | Cynosure, Inc. | Endoscopic light delivery system |
US5495541A (en) * | 1994-04-19 | 1996-02-27 | Murray; Steven C. | Optical delivery device with high numerical aperture curved waveguide |
US5509917A (en) * | 1994-06-28 | 1996-04-23 | Ceramoptec Industries, Inc. | Lensed caps for radial medical laser delivery devices |
US5757827A (en) * | 1994-07-26 | 1998-05-26 | Hitachi Metals, Ltd. | Second harmonic generating apparatus and apparatus employing laser |
US5632739A (en) * | 1994-10-13 | 1997-05-27 | The General Hospital Corporation | Two-pulse, lateral tissue illuminator |
US5776127A (en) * | 1994-10-13 | 1998-07-07 | The General Hospital Corporation | Two-pulse, lateral tissue illuminator |
US5772658A (en) * | 1994-12-20 | 1998-06-30 | Laser Industries, Ltd. | Side-emitting optical fibers for lasers |
US5733279A (en) * | 1994-12-21 | 1998-03-31 | Laser Industries, Ltd. | Device for treating the interior of body cavities with laser energy |
US5668903A (en) * | 1994-12-22 | 1997-09-16 | Ceramoptec Industries, Inc. | Compound laser system for high power densities |
US5746760A (en) * | 1995-01-17 | 1998-05-05 | Laserscope | Semi-automatic tissue morcellation device |
US5879376A (en) * | 1995-07-12 | 1999-03-09 | Luxar Corporation | Method and apparatus for dermatology treatment |
US5658323A (en) * | 1995-07-12 | 1997-08-19 | Miller; Iain D. | Method and apparatus for dermatology treatment |
US6027495A (en) * | 1995-07-12 | 2000-02-22 | Esc Medical Systems Ltd. | Method and apparatus for dermatology treatment |
US5841800A (en) * | 1995-07-28 | 1998-11-24 | Laserscope | Desktop medical laser generator |
US5798518A (en) * | 1995-07-28 | 1998-08-25 | Laserscope | Medical laser calibration system and method |
US5776175A (en) * | 1995-09-29 | 1998-07-07 | Esc Medical Systems Ltd. | Method and apparatus for treatment of cancer using pulsed electromagnetic radiation |
US5778395A (en) * | 1995-10-23 | 1998-07-07 | Stac, Inc. | System for backing up files from disk volumes on multiple nodes of a computer network |
US5895356A (en) * | 1995-11-15 | 1999-04-20 | American Medical Systems, Inc. | Apparatus and method for transurethral focussed ultrasound therapy |
US6086580A (en) * | 1996-12-05 | 2000-07-11 | Centre International De Recherches Dermatologiques | Laser treatment/ablation of skin tissue |
US6024751A (en) * | 1997-04-11 | 2000-02-15 | Coherent Inc. | Method and apparatus for transurethral resection of the prostate |
US6482199B1 (en) * | 1997-06-04 | 2002-11-19 | Joseph Neev | Method and apparatus for high precision variable rate material, removal and modification |
US6011890A (en) * | 1997-08-06 | 2000-01-04 | Ceram Optec Industries, Inc. | High power, multi-diode laser system |
US6064914A (en) * | 1998-04-01 | 2000-05-16 | Trachtenberg; John R. | Thermotherapy method |
US6699239B1 (en) * | 1998-05-18 | 2004-03-02 | Dornier Medtech Systems Gmbh | Laser instrument |
US6379347B1 (en) * | 1998-05-28 | 2002-04-30 | Terumo Kabushiki Kaisha | Energy irradiation apparatus |
US6596017B1 (en) * | 1998-09-10 | 2003-07-22 | Prostalund Operations Ab | Device for heat treatment of body tissue |
US6389313B1 (en) * | 1999-03-26 | 2002-05-14 | Kevin S. Marchitto | Laser probes for drug permeation |
US6423055B1 (en) * | 1999-07-14 | 2002-07-23 | Cardiofocus, Inc. | Phototherapeutic wave guide apparatus |
US6530921B1 (en) * | 1999-07-30 | 2003-03-11 | Terumo Kabushiki Kaisha | Laser irradiation apparatus |
US6554825B1 (en) * | 2000-05-09 | 2003-04-29 | Laserscope | Variable pulse duration, adjustable wavelength medical laser system |
US6554824B2 (en) * | 2000-12-15 | 2003-04-29 | Laserscope | Methods for laser treatment of soft tissue |
US20050288653A1 (en) * | 2004-06-23 | 2005-12-29 | Applied Harmonics Corporation | Apparatus and method for soft tissue ablation employing high power diode-pumped laser |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050288653A1 (en) * | 2004-06-23 | 2005-12-29 | Applied Harmonics Corporation | Apparatus and method for soft tissue ablation employing high power diode-pumped laser |
US8137340B2 (en) * | 2004-06-23 | 2012-03-20 | Applied Harmonics Corporation | Apparatus and method for soft tissue ablation employing high power diode-pumped laser |
US20080086118A1 (en) * | 2006-05-17 | 2008-04-10 | Applied Harmonics Corporation | Apparatus and method for diode-pumped laser ablation of soft tissue |
WO2012095873A1 (en) | 2011-01-11 | 2012-07-19 | Quanta System S.P.A. | Laser surgery device |
US8932063B2 (en) | 2011-04-15 | 2015-01-13 | Ams Research Corporation | BPH laser ablation simulation |
KR101530650B1 (en) * | 2014-08-28 | 2015-06-22 | 인덕대학교 산학협력단 | Medical laser irradiation device |
US11389241B2 (en) | 2019-01-15 | 2022-07-19 | Boston Scientific Scimed, Inc. | Alignment method and tools |
US11844494B2 (en) | 2019-01-15 | 2023-12-19 | Boston Scientific Scimed, Inc. | Alignment method and tools |
Also Published As
Publication number | Publication date |
---|---|
US20140221989A1 (en) | 2014-08-07 |
US20040236319A1 (en) | 2004-11-25 |
US6986764B2 (en) | 2006-01-17 |
US20040236318A1 (en) | 2004-11-25 |
US20080262485A1 (en) | 2008-10-23 |
US10653482B2 (en) | 2020-05-19 |
US20060084959A1 (en) | 2006-04-20 |
US20050027286A1 (en) | 2005-02-03 |
US20030135205A1 (en) | 2003-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10653482B2 (en) | System for vaporization of tissue | |
EP1349509B1 (en) | Laser treatment of soft tissue | |
US20050256513A1 (en) | Method and system for vaporization of tissue using direct visualization | |
US7063694B2 (en) | Method and system for photoselective vaporization for gynecological treatments | |
US8137340B2 (en) | Apparatus and method for soft tissue ablation employing high power diode-pumped laser | |
US5754573A (en) | Method and apparatus for treating vascular lesions | |
US20080086118A1 (en) | Apparatus and method for diode-pumped laser ablation of soft tissue | |
US8881735B2 (en) | Flash vaporization surgical systems and method | |
US20080021527A1 (en) | Endovenous laser treatment generating reduced blood coagulation | |
CN102695468B (en) | Melt/solidify urinary system therapy equipment and method | |
EP2358286B1 (en) | Dynamic laser pulse systems | |
RU2315582C1 (en) | Laser assembly | |
CN1891173A (en) | Fixed laser soft tissue therapeutic apparatus of double wavelength continuous pumping and method therefor | |
Goebel | Fundamentals of laser science | |
CN109602491B (en) | Dual-wavelength high-power surgical instrument for laser ablation of prostate | |
Colt | Basic principles of medical lasers | |
KR20050089309A (en) | Continuous-pumped dual-wavelength solid-state laser apparatus for treatment of soft tissue |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AS | Assignment |
Owner name: MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRA Free format text: SECURITY AGREEMENT;ASSIGNOR:AMS RESEARCH CORPORATION;REEL/FRAME:026632/0535 Effective date: 20110617 |
|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: AMS RESEARCH CORPORATION, MINNESOTA Free format text: RELEASE OF PATENT SECURITY INTEREST;ASSIGNOR:MORGAN STANLEY SENIOR FUNDING, INC., AS ADMINISTRATIVE AGENT;REEL/FRAME:032380/0053 Effective date: 20140228 |